UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Form 10-Q

~~[X]~~☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

~~September~~

June 30, ~~2020~~

2021

~~[ ]~~☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No.

~~111596~~

001-11596

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Delaware	~~58-1954497~~
(State or other jurisdiction	~~(IRS Employer~~
of incorporation or organization)	58-1954497 (IRS Employer Identification Number)


8302 Dunwoody Place, Suite 250, Atlanta, GA	~~30350~~
(Address of principal executive offices)	30350 ~~(Zip~~(Zip Code)

~~(770)~~ (770) 587-9898

(Registrant’s telephone number)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

~~Securities registered pursuant to Section 12(b) of the Act:~~

Title of each class	Trading Symbol	Name of each exchange on which registered

Common Stock, $.001 Par Value	PESI	NASDAQ Capital Markets
~~Preferred Stock Purchase Rights~~		~~NASDAQ Capital Markets~~

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).

Yes ~~[X]~~ ☒ No ~~[ ]~~☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ~~[ ]~~☐ Accelerated Filer ~~[ ]~~ ☐ Non-accelerated Filer ~~[ ]~~ ☒ Smaller reporting company ~~[X]~~☒ Emerging growth company ~~[ ]~~☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act ~~[ ]~~☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ~~[ ]~~ ☐ No ~~[X]~~ ☒

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the close of the latest practical date.

Class		Outstanding at ~~November 4, 2020~~July 30, 2021
Common Stock, $.001 Par Value		~~12,153,897~~12,196,623 shares

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

INDEX

			Page No.
PART I		FINANCIAL INFORMATION

	Item 1.	Consolidated Financial Statements	3

		Consolidated Balance Sheets - ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020	31

		Consolidated Statements of Operations - Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020	5 3

		Consolidated Statements of Comprehensive Income - Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020	6 4

		Consolidated ~~Statement~~Statements of Stockholders’ Equity - ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020	7 5

		Consolidated Statements of Cash Flows - ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020	86

		Notes to Consolidated Financial Statements	97

	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of ~~Operation~~Operations	29 23

	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4536

	Item 4.	Controls and Procedures	4536

PART II		OTHER INFORMATION

	Item 1.	Legal Proceedings	4537

	Item 1A.	Risk Factors	4637

	Item 6.	Exhibits	4637

PART I - FINANCIAL INFORMATION

~~ITEM~~Item 1. – Financial Statements

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Balance Sheets

	September 30,			December 31,			June 30,			December 31,
	2020			2019			2021			2020
(Amounts in Thousands, Except for Share and Per Share Amounts)	(Unaudited)			(Audited)			(Unaudited)			(Audited)

ASSETS
Current assets:
Cash	$	4,811		$	390		$	7,312		$	7,924
Accounts receivable, net of allowance for doubtful accounts of $432 and $487, respectively		13,442			13,178
Accounts receivable, net of allowance for doubtful accounts of $27 and $404, respectively								9,244			9,659
Unbilled receivables		14,366			7,984			7,332			14,453
Inventories		525			487			701			610
Prepaid and other assets		3,863			2,983			2,926			3,967
Current assets related to discontinued operations		17			104			17			22
Total current assets		37,024			25,126			27,532			36,635

Property and equipment:
Buildings and land		20,049			19,967			20,123			20,139
Equipment		22,285			20,068			22,132			22,090
Vehicles		456			410			454			457
Leasehold improvements		23			23			23			23
Office furniture and equipment		1,470			1,418			1,425			1,413
Construction-in-progress		1,513			1,609			2,227			1,569
Total property and equipment		45,796			43,495			46,384			45,691
Less accumulated depreciation		(27,900	)		(26,919	)		(28,574	)		(27,908	)
Net property and equipment		17,896			16,576			17,810			17,783

Property and equipment related to discontinued operations		81			81			81			81

Operating lease right-of-use assets		2,353			2,545			2,317			2,287

Intangibles and other long term assets:
Permits		8,875			8,790			9,118			8,922
Other intangible assets - net		923			1,065			885			875
Finite risk sinking fund (restricted cash)		11,418			11,307			11,467			11,446
Other assets		911			989			849			890
Other assets related to discontinued operations		—			36
Total assets	$	79,481		$	66,515		$	70,059		$	78,919

The accompanying notes are an integral part of these consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Balance Sheets, Continued

	September 30,			December 31,			June 30,			December 31,
	2020			2019			2021			2020
(Amounts in Thousands, Except for Share and Per Share Amounts)	(Unaudited)			(Audited)
(Amounts in Thousands, Except for Share and per Share Amounts)							(Unaudited)			(Audited)

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	14,652		$	9,277		$	11,511		$	15,382
Accrued expenses		6,743			6,118			5,637			6,381
Disposal/transportation accrual		1,041			1,156			1,055			1,220
Deferred revenue		4,806			5,456			3,932			4,614
Accrued closure costs - current		75			84			74			75
Current portion of long-term debt		828			1,300			404			3,595
Current portion of operating lease liabilities		265			244			275			273
Current portion of finance lease liabilities		675			471			433			525
Current liabilities related to discontinued operations		919			994			817			898
Total current liabilities		30,004			25,100			24,138			32,963

Accrued closure costs		6,207			5,957			6,465			6,290
Deferred tax liabilities		588			590			474			471
Long-term debt, less current portion		6,426			2,580			819			3,134
Long-term operating lease liabilities, less current portion		2,141			2,342			2,119			2,070
Long-term finance lease liabilities, less current portion		715			466			555			662
Other long-term liabilities		838			—			626			626
Long-term liabilities related to discontinued operations		250			244			256			252
Total long-term liabilities		17,165			12,179			11,314			13,505

Total liabilities		47,169			37,279			35,452			46,468

Commitments and Contingencies (Note 10)
Commitments and Contingencies (Note 9)

Stockholders’ Equity:
Preferred Stock, $.001 par value; 2,000,000 shares authorized, no shares issued and outstanding		—			—
Common Stock, $.001 par value; 30,000,000 shares authorized; 12,152,363 and 12,123,520 shares issued, respectively; 12,144,721 and 12,115,878 shares outstanding, respectively		12			12
Preferred Stock, $.001 par value; 2,000,000 shares authorized, 0 shares issued and outstanding								—			—
Common Stock, $.001 par value; 30,000,000 shares authorized;12,188,256 and 12,161,539 shares issued, respectively;12,180,614 and 12,153,897 shares outstanding, respectively								12			12
Additional paid-in capital		108,790			108,457			109,206			108,931
Accumulated deficit		(74,445	)		(77,315	)		(72,555	)		(74,455	)
Accumulated other comprehensive loss		(251	)		(211	)		(167	)		(207	)
Less Common Stock in treasury, at cost; 7,642 shares		(88	)		(88	)		(88	)		(88	)
Total Perma-Fix Environmental Services, Inc. stockholders’ equity		34,018			30,855			36,408			34,193
Non-controlling interest		(1,706	)		(1,619	)		(1,801	)		(1,742	)
Total stockholders’ equity		32,312			29,236			34,607			32,451

Total liabilities and stockholders’ equity	$	79,481		$	66,515		$	70,059		$	78,919

The accompanying notes are an integral part of these consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Operations

(Unaudited)


	Three Months Ended						Nine Months Ended						Three Months Ended						Six Months Ended
	September 30,						September 30,						June 30,						June 30,
(Amounts in Thousands, Except for Per Share Amounts)	2020			2019			2020			2019			2021			2020			2021			2020

Net revenues	$	30,172		$	22,535		$	77,079		$	51,378		$	16,145		$	22,047		$	39,278		$	46,907
Cost of goods sold		25,422			17,378			64,379			40,449			15,179			18,737			35,956			38,957
Gross profit		4,750			5,157			12,700			10,929			966			3,310			3,322			7,950

Selling, general and administrative expenses		3,308			2,945			8,935			8,548			2,997			2,700			6,202			5,627
Research and development		157			165			598			615			144			209			295			441
Loss on disposal of property and equipment		—			4			27			3
Income from operations		1,285			2,043			3,140			1,763
(Gain) loss on disposal of property and equipment														—			(4)			—			27
(Loss) income from operations														(2,175	)		405			(3,175	)		1,855

Other income (expense):
Interest income		28			77			112			265			2			28			21			84
Interest expense		(87	)		(99	)		(306	)		(293	)		(65	)		(99	)		(132	)		(219	)
Interest expense-financing fees		(58	)		(69	)		(187	)		(139	)		(9	)		(60	)		(17	)		(129	)
Other		180			(2	)		189			222			—			4			1			9
Loss on debt extinguishment of debt		—			—			(27	)		—
Gain (loss) on extinguishment of debt														5,381			(27	)		5,381			(27	)
Income from continuing operations before taxes		1,348			1,950			2,921			1,818			3,134			251			2,079			1,573
Income tax (benefit) expense		(133	)		55			(128	)		99
Income tax expense (benefit)														13			(9	)		(4	)		5
Income from continuing operations, net of taxes		1,481			1,895			3,049			1,719			3,121			260			2,083			1,568

Loss from discontinued operations, net of taxes of $0		(67	)		(156	)		(266	)		(424	)
Loss from discontinued operations (net of taxes of $0)														(127	)		(85	)		(242	)		(199	)
Net income		1,414			1,739			2,783			1,295			2,994			175			1,841			1,369

Net loss attributable to non-controlling interest		(32	)		(29	)		(87	)		(90	)		(29	)		(29	)		(59	)		(55	)

Net income attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	1,446		$	1,768		$	2,870		$	1,385		$	3,023		$	204		$	1,900		$	1,424

Net income (loss) per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - basic:
Continuing operations	$	.13		$	.16		$	.26		$	.15		$	.26		$	.02		$	.18		$	.13
Discontinued operations		(.01	)		(.01	)		(.02	)		(.03	)		(.01	)		—			(.02	)		(.01	)
Net income per common share	$	.12		$	.15		$	.24		$	.12		$	.25		$	.02		$	.16		$	.12

Net income (loss) per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - diluted:

Continuing operations	$	.13		$	.16		$	.25		$	.15		$	.25		$	.02		$	.17		$	.13
Discontinued operations		(.01	)		(.01	)		(.02	)		(.04	)		(.01	)		—			(.02	)		(.01)
Net income per common share	$	.12		$	.15		$	.23		$	.11		$	.24		$	.02		$	.15		$	.12

Number of common shares used in computing net income per share:
Basic		12,145			12,070			12,134			12,029			12,180			12,135			12,173			12,129
Diluted		12,371			12,123			12,337			12,061			12,440			12,286			12,420			12,320

~~The accompanying notes are an integral part of these consolidated financial statements.~~

~~PERMA-FIX ENVIRONMENTAL SERVICES, INC.~~

~~Consolidated Statements of Comprehensive Income~~

~~(Unaudited)~~

Three Months Ended Nine Months Ended
September 30, September 30,
(Amounts in Thousands) 2020 2019 2020 2019

Net income $ 1,414 $ 1,739 $ 2,783 $ 1,295
Other comprehensive income (loss):
Foreign currency translation adjustment 11 4 (40 ) 12

Comprehensive income 1,425 1,743 2,743 1,307
Comprehensive loss attributable to non-controlling interest (32 ) (29 ) (87 ) (90 )
Comprehensive income attributable to Perma-Fix Environmental Services, Inc. stockholders $ 1,457 $ 1,772 $ 2,830 $ 1,397

~~The accompanying notes are an integral part of these consolidated financial statements.~~

~~PERMA-FIX ENVIRONMENTAL SERVICES, INC~~

~~Consolidated Statement of Stockholders’ Equity~~

~~(Unaudited)~~

~~(Amounts in thousands, except for share amounts)~~

Common Stock Additional Paid-In
Common Stock
Held In
Accumulated Other Comprehensive Non-controlling Interest in Accumulated Total Stockholders’
Shares Amount Capital Treasury Loss Subsidiary Deficit Equity

Balance at December 31, 2019 12,123,520 $ 12 $ 108,457 $ (88 ) $ (211 ) $ (1,619 ) $ (77,315 ) $ 29,236
Net Income (loss) — — — — — (26 ) 1,220 1,194
Foreign currency translation — — — — (79 ) — — (79 )
Issuance of Common Stock upon exercise of options 3,643 — 6 — — — — 6
Issuance of Common Stock for services 5,128 — 48 — — — — 48
Stock-Based Compensation — — 44 — — — — 44
Balance at March 31, 2020 12,132,291 $ 12 $ 108,555 $ (88 ) $ (290 ) $ (1,645 ) $ (76,095 ) $ 30,449
Net Income (loss) — — — — — (29 ) 204 175
Foreign currency translation — — — — 28 — — 28
Issuance of Common Stock upon exercise of options 241 — — — — — — —
Issuance of Common Stock for services 10,239 — 56 — — — — 56
Stock-Based Compensation — — 48 — — — — 48
Balance at June 30, 2020 12,142,771 $ 12 $ 108,659 $ (88 ) $ (262 ) $ (1,674 ) $ (75,891 ) $ 30,756
Net Income (loss) — — — — — (32 ) 1,446 1,414
Foreign currency translation — — — — 11 — — 11
Issuance of Common Stock for services 9,592 — 62 — — — — 62
Stock-Based Compensation — — 69 — — — — 69
Balance at September 30, 2020 12,152,363 $ 12 $ 108,790 $ (88 ) $ (251 ) $ (1,706 ) $ (74,445 ) $ 32,312

Balance at December 31, 2018 11,944,215 $ 12 $ 107,548 $ (88 ) $ (214 ) $ (1,495 ) $ (79,630 ) $ 26,133
Net loss — — — — — (30 ) (672 ) (702 )
Foreign currency translation — — — — 12 — — 12
Issuance of Common Stock for services 24,964 — 60 — — — — 60
Stock-Based Compensation — — 48 — — — — 48
Balance at March 31, 2019 11,969,179 $ 12 $ 107,656 $ (88 ) $ (202 ) $ (1,525 ) $ (80,302 ) $ 25,551
Net income (loss) — — — — — (31 ) 289 258
Foreign currency translation — — — — (4 ) — — (4 )
Issuance of Common Stock for services 17,902 — 62 — — — — 62
Stock-Based Compensation — — 36 — — — — 36
Issuance of Common Stock with debt 75,000 — 263 — — — — 263
Issuance of warrant with debt — — 93 — — — — 93
Balance at June 30, 2019 12,062,081 $ 12 $ 108,110 $ (88 ) $ (206 ) $ (1,556 ) $ (80,013 ) $ 26,259
Net income (loss) — — — — — (29 ) 1,768 1,739
Foreign currency translation — — — — 4 — — 4
Issuance of Common Stock for services 15,337 — 60 — — — — 60
Stock-Based Compensation — — 45 — — — — 45
Balance at September 30, 2019 12,077,418 $ 12 $ 108,215 $ (88 ) $ (202 ) $ (1,585 ) $ (78,245 ) $ 28,107

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of ~~Cash Flows~~Comprehensive Income

(Unaudited)

Nine Months Ended
September 30,
(Amounts in Thousands) 2020 2019
Cash flows from operating activities:
Net income $ 2,783 $ 1,295
Less: loss from discontinued operations, net of taxes of $0 (266 ) (424 )

Income from continuing operations, net of taxes 3,049 1,719
Adjustments to reconcile income from continuing operations to cash provided by (used in) operating activities:
Depreciation and amortization 1,189 968
Interest on finance lease with purchase option 6 —
Loss on extinguishment of debt 27 —
Amortization of debt issuance/debt discount costs 187 139
Deferred tax (benefit) expense (2 ) 26
(Recovery of) provision for bad debt reserves (94 ) 147
Loss on disposal of property and equipment 27 3
Issuance of common stock for services 166 182
Stock-based compensation 161 129
Changes in operating assets and liabilities of continuing operations
Accounts receivable (170 ) (3,193 )
Unbilled receivables (6,382 ) (6,140 )
Prepaid expenses, inventories and other assets 1,284 500
Accounts payable, accrued expenses and unearned revenue 4,055 2,516
Cash provided by (used in) continuing operations 3,503 (3,004 )
Cash used in discontinued operations (329 ) (459 )
Cash provided by (used in) operating activities 3,174 (3,463 )

Cash flows from investing activities:
Purchases of property and equipment (1,488 ) (813 )
Proceeds from sale of property and equipment 4 1
Cash used in investing activities of continuing operations (1,484 ) (812 )
Cash provided by investing activities of discontinued operations 118 100
Cash used in investing activities (1,366 ) (712 )

Cash flows from financing activities:
Repayments of revolving credit borrowings (72,601 ) (38,378 )
Borrowing on revolving credit 72,280 37,739
Proceeds from issuance of long-term debt 5,666 2,500
Proceeds from finance leases — 405
Principal repayments of finance lease liabilities (411 ) (174 )
Principal repayments of long term debt (2,127 ) (925 )
Payment of debt issuance costs (85 ) (112 )
Proceeds from issuance of common stock upon exercise of options 6 —
Cash provided by financing activities of continuing operations 2,728 1,055

Effect of exchange rate changes on cash (4 ) 16

Increase (decrease) in cash and finite risk sinking fund (restricted cash) 4,532 (3,104 )
Cash and finite risk sinking fund (restricted cash) at beginning of period 11,697 16,781
Cash and finite risk sinking fund (restricted cash) at end of period $ 16,229 $ 13,677

Supplemental disclosure:
Interest paid $ 286 $ 284
Income taxes paid 34 168
Equipment purchase subject to finance lease 856 29
Equipment purchase subject to financing 27 —
Issuance of Common Stock with debt — 263
Issuance of Warrant with debt — 93


	Three Months Ended						Six Months Ended
	June 30,						June 30,
(Amounts in Thousands)	2021			2020			2021			2020

Net income	$	2,994		$	175		$	1,841		$	1,369
Other comprehensive income (loss):
Foreign currency translation gain (loss)		20			28			40			(51	)

Comprehensive income		3,014			203			1,881			1,318
Comprehensive loss attributable to non-controlling interest		(29	)		(29	)		(59	)		(55	)
Comprehensive income attributable to Perma-Fix Environmental Services, Inc. stockholders	$	3,043		$	232		$	1,940		$	1,373

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC

Consolidated Statement of Stockholders’ Equity

(Unaudited)

(Amounts in thousands, except for share amounts)


	Common Stock				Additional Paid-In		Common Stock Held In			Accumulated Other Comprehensive			Non-controlling Interest in			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Treasury			Loss			Subsidiary			Deficit			Equity

Balance at December 31, 2020		12,161,539	$	12	$	108,931	$	(88	)	$	(207	)	$	(1,742	)	$	(74,455	)	$	32,451
Net loss		—		—		—		—			—			(30	)		(1,123	)		(1,153	)
Net Income (loss)		—		—		—		—			—			(30	)		(1,123	)		(1,153	)
Foreign currency translation		—		—		—		—			20			—			—			20
Issuance of Common Stock for services		11,837		—		79		—			—			—			—			79
Stock-Based Compensation		—		—		45		—			—			—			—			45
Balance at March 31, 2021		12,173,376	$	12	$	109,055	$	(88	)	$	(187	)	$	(1,772	)	$	(75,578	)	$	31,442
Net Income (loss)		—		—		—		—			—			(29	)		3,023			2,994
Foreign currency translation		—		—		—		—			20			—			—			20
Issuance of Common Stock upon exercise of options		290		—		—		—			—			—			—			—
Issuance of Common Stock for services		14,590		—		109		—			—			—			—			109
Stock-Based Compensation		—		—		42		—			—			—			—			42
Balance at June 30, 2021		12,188,256	$	12	$	109,206	$	(88	)	$	(167	)	$	(1,801	)	$	(72,555	)	$	34,607

Balance at December 31, 2019		12,123,520	$	12	$	108,457	$	(88	)	$	(211	)	$	(1,619	)	$	(77,315	)	$	29,236
Net Income (loss)		—		—		—		—			—			(26	)		1,220			1,194
Foreign currency translation		—		—		—		—			(79	)		—			—			(79	)
Issuance of Common Stock upon exercise of options		3,643		—		6		—			—			—			—			6
Issuance of Common Stock for services		5,128		—		48		—			—			—			—			48
Stock-Based Compensation		—		—		44		—			—			—			—			44
Balance at March 31, 2020		12,132,291	$	12	$	108,555	$	(88	)	$	(290	)	$	(1,645	)	$	(76,095	)	$	30,449
Net Income (loss)		—		—		—		—			—			(29	)		204			175
Foreign currency translation		—		—		—		—			28			—			—			28
Issuance of Common Stock upon exercise of options		241		—		—		—			—			—			—			—
Issuance of Common Stock for services		10,239		—		56		—			—			—			—			56
Stock-Based Compensation		—		—		48		—			—			—			—			48
Balance at June 30, 2020		12,142,771	$	12	$	108,659	$	(88	)	$	(262	)	$	(1,674	)	$	(75,891	)	$	30,756

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Cash Flows

(Unaudited)


	Six Months Ended
	June 30,
(Amounts in Thousands)	2021			2020
Cash flows from operating activities:
Net income	$	1,841		$	1,369
Less: loss from discontinued operations, net of taxes of $0		(242	)		(199	)

Income from continuing operations, net of taxes		2,083			1,568
Adjustments to reconcile income from continuing operations to cash provided by operating activities:
Depreciation and amortization		799			711
Interest on finance lease with purchase option		4			4
(Gain) loss on extinguishment of debt		(5,381	)		27
Amortization of debt discount/debt issuance costs		17			129
Deferred tax expense		3			5
Recovery of bad debt reserves		(17	)		(107	)
Loss on disposal of property and equipment		—			27
Issuance of common stock for services		188			104
Stock-based compensation		87			92
Changes in operating assets and liabilities of continuing operations
Accounts receivable		432			2,479
Unbilled receivables		7,121			(3,085	)
Prepaid expenses, inventories and other assets		1,076			714
Accounts payable, accrued expenses and unearned revenue		(5,609	)		289
Cash provided by continuing operations		803			2,957
Cash used in discontinued operations		(315	)		(259	)
Cash provided by operating activities		488			2,698

Cash flows from investing activities:
Purchases of property and equipment		(650	)		(1,366	)
Proceeds from sale of property and equipment		1			4
Cash used in investing activities of continuing operations		(649	)		(1,362	)
Cash provided by investing activities of dicontinued operations		—			13
Cash used in investing activities		(649	)		(1,349	)

Cash flows from financing activities:
Repayments of revolving credit borrowings		(41,834	)		(47,058	)
Borrowing on revolving credit		41,834			46,737
Proceeds from issuance of long-term debt		—			5,666
Principal repayments of finance lease liabilities		(205	)		(229	)
Principal repayments of long term debt		(219	)		(1,045	)
Payment of debt issuance costs		(15	)		(85	)
Proceeds from issuance of common stock upon exercise of options		—			6
Cash (used in) provided by financing activities of continuing operations		(439	)		3,992

Effect of exchange rate changes on cash		9			(18	)

(Decrease) increase in cash and finite risk sinking fund (restricted cash)		(591	)		5,323
Cash and finite risk sinking fund (restricted cash) at beginning of period		19,370			11,697
Cash and finite risk sinking fund (restricted cash) at end of period	$	18,779		$	17,020

Supplemental disclosure:
Interest paid	$	106		$	207
Income taxes paid		15			30
Non-cash financing activities:
Equipment purchase subject to finance lease		—			132
Equipment purchase subject to finance		29			—

The accompanying notes are an integral part of these condensed consolidated financial statements.

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Notes to Consolidated Financial Statements

~~September~~June 30, ~~2020~~2021

(Unaudited)

Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020.

1.	~~Basis of Presentation~~

1. Basis of Presentation

The consolidated financial statements included herein have been prepared by the Company (which may be referred to as we, us or our), without an audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“the Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes the disclosures which are made are adequate to make the information presented not misleading. Further, the consolidated financial statements reflect, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 are not necessarily indicative of results to be expected for the fiscal year ending December 31, ~~2020.~~2021.

The Company suggests that these consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020.

The consolidated financial statements include our accounts, those of our wholly-owned subsidiaries, and our majority-owned Polish subsidiary, Perma-Fix Medical. Additionally, the Company’s financial statements include the account of a variable interest entity (“VIE”), Perma-Fix ERRG for which we are the primary beneficiary (See “Note 1413 - VIE” for a discussion of this VIE).

2.	~~Summary of Significant Accounting Policies~~

2. Summary of Significant Accounting Policies

Our accounting policies are as set forth in the notes to the December 31, 2020 consolidated financial statements referred to above.

Recently Adopted Accounting Standards

In ~~August 2018,~~December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ~~2018-13, “Fair Value Measurement~~No. 2019-12, “Income Taxes (Topic ~~820)~~740): ~~Disclosure Framework - Changes~~Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the ~~Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 improves the disclosure requirements on fair value measurements. ASU 2018-13~~general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, ~~2019.~~2020, with early adoption permitted. The adoption of ASU No. ~~2018-13~~2019-12 by the Company effective January 1, 2021 did not have a material impact on the Company’s financial statements.

In January 2020, the FASB issued ASU 2020-01, “Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The adoption of ASU No. 2020-01 by the Company effective January 1, 2021 did not have a material impact on the Company’s financial statements.

In October 2020, the FASB issued ASU No 2020-10, “Codification Improvements.” ASU 2020-10 updates various codification topics by clarifying or improving disclosure requirements. ASU 2020-10 is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. The adoption of ASU No. 2020-01 by the Company effective January 1, 2021 did not have a material impact on the Company’s financial statements or disclosures.

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (“ASU 848”): Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference London Interbank Offered Rate (“LIBOR”) or another rate that is expected to be discontinued. The amendments in the ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The adoption of ASU 2020-04 on March 12, 2020 by the Company did not have a material impact on the Company’s financial statements. The Company will continue to assess the potential impact of this ASU through the effective period.

Recently Issued Accounting Standards – Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, “Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments,” and various subsequent amendments to the initial guidance: ASU 2018-19 “Codification Improvements to Topic 326, Financial Instruments - Credit Losses,” ASU 2019-04 “Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,” ASU 2019-05 “Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief,” ASU 2019-11 “Codification Improvements to Topic 326, Financial Instruments - Credit Losses” and ASU 2020-02, “Financial Instruments—Credit Losses (Topic 326) and Leases (Topic 842)”guidance (collectively, “Topic 326”). Topic 326 introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables and loans. Entities are required to apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. In November 2019, FASB issued ASU 2019-10, “Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date of ASU 2016-13 for public companies that are considered smaller reporting companies as defined by the Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. These ASUs are effective January 1, 2023 for the Company as a smaller reporting ~~company.~~company (“SRC”). Under new guidance issued by the Commission in March 2020, the Company will continue to qualify as a smaller reporting company but will also be an accelerated filer for all filings with the Commission after January 1, 2022. The Company ~~had expected to early adopt theses ASUs effective January 1, 2020; however, due to~~is currently evaluating the ~~need for reallocation~~impact of ~~the Company’s resources to manage COVID-19 related matters, the Company has deferred adoption of theses ASUs effective January 1, 2020 and expect to adopt~~ these ~~ASUs by January 1, 2023.~~

~~In December 2019, the FASB issued~~ ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company does not expect the adoption of this ASU will have a material impact on ~~the Company’s~~its consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, “Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), clarifying the Interactions between Topic 321, Topic 323, and Topic 815.” This guidance addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company does not expect the adoption of this ASU will have a material impact on the Company’s financial statements.

In August 2020, the FASB issued ASU No. 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models and removing certain settlement condition qualifiers for the derivatives scope exception for contracts in an entity’s own equity, and simplifies the related diluted net income per share calculation for both Subtopics. ASU 2020-06 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, for the Company as a smaller reporting company. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and disclosures.

3. ~~COVID-19 Impact~~

~~The spread~~In May 2021, the FASB issued ASU No. 2021-04, “Earnings Per Share (Topic 206), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of ~~COVID-19 continues to result in significant volatility in~~Freestanding Equity-Classified Written Call Options (a consensus of the ~~U.S. and international markets.~~FASB Emerging Issues Task Force).” ASU 2021-04 addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This ASU is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The Company ~~continues to closely monitor~~is currently evaluating the impact of ~~the COVID-19 pandemic~~this ASU on ~~all aspects of~~ its business. As previously reported, the COVID-19 pandemic did not result in a material impact to the Company’s first quarter 2020 results of operations. Starting in late March 2020, the Company’s operations were impacted by the shutdown of a number of projects and the delays of certain waste shipments that continued into the second quarter of 2020. Since the latter part of the second quarter of 2020, all of the projects that were previously shutdown within our Services Segment have restarted as stay-at-home orders and certain other restrictions resulting from the pandemic were lifted. Revenues within our Services Segment in the third quarter of 2020 exceeded the corresponding period of 2019 by approximately $10,652,000. The Company continues to experience delays in waste shipments from certain customers within our Treatment Segment directly related to the impact of COVID-19 including generator shutdowns and limited sustained operations, along with other factors. These waste shipment delays may impact the Company’s results of operations for the fourth quarter of 2020 and potentially the first quarter of 2021.consolidated financial statements.

At this time, the Company believes it has sufficient liquidity on hand to continue business operations during the next twelve months. At September 30, 2020, the Company had cash on hand of approximately $4,811,000 and borrowing availability under our revolving credit facility of approximately $16,404,000 based on a percentage of eligible receivables and subject to certain reserves. The Company continues to assess reducing operating costs during this volatile time, which include curtailing capital expenditures, eliminating non-essential expenditures and implementing a hiring freeze as needed.3. Revenue

The Company is closely monitoring our customers’ payment performance. However, as a significant portion of our revenues is derived from government related contracts, the Company does not expect its accounts receivable collections to be materially impacted due to COVID-19.

The situation surrounding COVID-19 continues to remain fluid. The potential for a material impact on the Company’s business increases the longer COVID-19 impacts the level of economic activities in the United States and globally as our customers may continue to delay waste shipments and project work may shut down again. For this reason, we cannot reasonably estimate with any degree of certainty the future impact COVID-19 may have on our results of operations, financial position, and liquidity which may impact our ability to meet our financial covenant requirements under our credit facility. Given the current economic environment and the market volatility from COVID-19, the Company considered whether these events or changes in circumstances triggered the need for an interim impairment analysis of our long-lived assets and intangible assets. Based on the Company’s assessment of the impact of these conditions on our business, the Company determined there was no triggering event as of September 30, 2020. However, as the effects of the COVID-19 pandemic continue to evolve, the Company will continue to assess the need to perform interim impairment tests of our long-lived assets and intangible assets.

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), as amended by the Paycheck Protection Program Flexibility Act of 2020 (the “Flexibility Act”) on June 5, 2020, provides the Company the option to defer the payment of its share of social security taxes beginning on March 27, 2020 through December 31, 2020. The Company elected to defer payment of its shares of social security taxes starting in April 2020 (see “Note 15 – Deferral of Employment Tax Deposits”). The Company also entered into a promissory note (“PPP Loan”) with its credit facility lender under the Paycheck Protection Program (“PPP”) that was established under the CARES Act, as amended (see “Note 9 – Long Term Debt – PPP Loan” for further detail of this loan).

4.	~~Revenue~~

Disaggregation of Revenue

In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of our services and provides meaningful disaggregation of each business segment’s results of operations. The nature of the Company’s performance obligations within our Treatment and Services Segments result in the recognition of our revenue primarily over time. The following tables present further disaggregation of our revenues by different categories for our Services and Treatment Segments:

Schedule of Disaggregation of Revenue

Revenue by Contract Type	Revenue by Contract Type
(In thousands)		Three Months Ended						Three Months Ended						Three Months Ended						Three Months Ended
		September 30, 2020						September 30, 2019						June 30, 2021						June 30, 2020
		Treatment		Services		Total		Treatment		Services		Total		Treatment		Services		Total		Treatment		Services		Total
Fixed price		$	7,066	$	10,303	$	17,369	$	10,081	$	5,364	$	15,445	$	7,706	$	1,482	$	9,188	$	7,840	$	2,329	$	10,169
Time and materials			—		12,803		12,803		—		7,090		7,090		—		6,957		6,957		—		11,878		11,878
Total		$	7,066	$	23,106	$	30,172	$	10,081	$	12,454	$	22,535	$	7,706	$	8,439	$	16,145	$	7,840	$	14,207	$	22,047

Revenue by Contract Type
Nine Months Ended Nine Months Ended
(In thousands) September 30, 2020 September 30, 2019
Treatment Services Total Treatment Services Total
Fixed price $ 24,469 $ 19,001 $ 43,470 $ 30,079 $ 9,231 $ 39,310
Time and materials — 33,609 33,609 — 12,068 12,068
Total $ 24,469 $ 52,610 $ 77,079 $ 30,079 $ 21,299 $ 51,378

Revenue by generator Three Months Ended Three Months Ended
(In thousands) September 30, 2020 September 30, 2019
Treatment Services Total Treatment Services Total
Domestic government $ 5,334 $ 21,660 $ 26,994 $ 7,537 $ 10,155 $ 17,692
Domestic commercial 1,598 459 2,057 2,535 475 3,010
Foreign government 134 966 1,100 — 1,804 1,804
Foreign commercial — 21 21 9 20 29
Total $ 7,066 $ 23,106 $ 30,172 $ 10,081 $ 12,454 $ 22,535

Revenue by generator Nine Months Ended Nine Months Ended
(In thousands) September 30, 2020 September 30, 2019
Treatment Services Total Treatment Services Total
Domestic government $ 19,079 $ 48,249 $ 67,328 $ 21,986 $ 15,683 $ 37,669
Domestic commercial 5,256 1,352 6,608 7,809 2,088 9,897
Foreign government 134 2,945 3,079 220 3,465 3,685
Foreign commercial — 64 64 64 63 127
Total $ 24,469 $ 52,610 $ 77,079 $ 30,079 $ 21,299 $ 51,378

Revenue by Contract Type
(In thousands)	Six Months Ended						Six Months Ended
	June 30, 2021						June 30, 2020
	Treatment		Services		Total		Treatment		Services		Total
Fixed price	$	15,201	$	4,063	$	19,264	$	17,403	$	3,721	$	21,124
Time and materials		—		20,014		20,014		—		25,783		25,783
Total	$	15,201	$	24,077	$	39,278	$	17,403	$	29,504	$	46,907

Revenue by generator
(In thousands)	Three Months Ended						Three Months Ended
	June 30, 2021						June 30, 2020
	Treatment		Services		Total		Treatment		Services		Total
Domestic government	$	5,639	$	6,764	$	12,403	$	6,055	$	12,791	$	18,846
Domestic commercial		2,060		391		2,451		1,785		431		2,216
Foreign government		7		1,261		1,268		—		965		965
Foreign commercial		—		23		23		—		20		20
Total	$	7,706	$	8,439	$	16,145	$	7,840	$	14,207	$	22,047

Revenue by generator
(In thousands)	Six Months Ended						Six Months Ended
	June 30, 2021						June 30, 2020
	Treatment		Services		Total		Treatment		Services		Total
Domestic government	$	10,237	$	19,425	$	29,662	$	13,745	$	26,589	$	40,334
Domestic commercial		4,328		981		5,309		3,658		893		4,551
Foreign government		541		3,625		4,166		—		1,979		1,979
Foreign commercial		95		46		141		—		43		43
Total	$	15,201	$	24,077	$	39,278	$	17,403	$	29,504	$	46,907

Contract Balances

The timing of revenue recognition, billings, and cash collections results in accounts receivable and unbilled receivables (contract assets). The Company’s contract liabilities consist of deferred revenues which represents advance payment from customers in advance of the completion of our performance obligation.

The following table represents changes in our contract assets and contract liabilities balances:

Schedule of Contract Assets and Liabilities

											June 30,		December 31,		Year-to-date			Year-to-date
(In thousands)	September 30, 2020		December 31, 2019		Year-to-date Change ($)			Year-to-date Change (%)			2021		2020		Change ($)			Change (%)
Contract assets
Account receivables, net of allowance	$	13,442	$	13,178	$	264			2.0	%	$	9,244	$	9,659	$	(415	)		(4.3	)%
Unbilled receivables - current		14,366		7,984		6,382			79.9	%		7,332		14,453		(7,121	)		(49.3	)%

Contract liabilities
Deferred revenue	$	4,806	$	5,456	$	(650	)		(11.9	)%	$	3,932	$	4,614	$	(682	)		(14.8	)%

During the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company recognized revenue of ~~$1,134,000~~$1,763,000 and ~~$7,673,000,~~$6,074,000, respectively, related to untreated waste that was in the Company’s control as of the beginning of ~~the~~each respective year. During the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, the Company recognized revenue of ~~$1,877,000~~$2,516,000 and ~~$9,322,000,~~$6,539,000, respectively, related to untreated waste that was in the Company’s control as of the beginning of ~~the~~each respective year. ~~All revenue~~Revenue recognized in each period related to performance obligations satisfied within the respective period.

Remaining Performance Obligations

The Company applies the practical expedient in ~~FASB Accounting Standards Codification (“ASC”)~~ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.

Within our Services Segment, there are service contracts which provide that the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of our performance completed to date. For those contracts, the Company has utilized the practical expedient in ASC 606-10-55-18, which allows the Company to recognize revenue in the amount for which we have the right to invoice; accordingly, the Company does not disclose the value of remaining performance obligations for those contracts.

4. Leases

5.	~~Leases~~

At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on facts and circumstances present in that arrangement. Lease classifications, recognition, and measurement are then determined at the lease commencement date.

The Company’s operating lease right-of-use (“ROU”) assets and operating lease liabilities represent primarily leases for office and warehouse spaces used to conduct our business. These leases have remaining terms of approximately 3 to 10 years which include one or more options to renew (which are included in valuing our ROU assets and liabilities). As most of our operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate as the discount rate when determining the present value of the lease payments. The incremental borrowing rate is determined based on the Company’s secured borrowing rate, lease terms and current economic environment. Lease expense for operating leases is recognized on a straight-line basis over the lease term.

Finance leases consist primarily ~~consist~~ of processing and transport equipment used by our facilities’ ~~operations. Our finance leases~~operations and also include a building with land for our waste treatment operations. The Company’s finance leases generally have initial terms between one to six years and some of the leases include options to purchase the underlying assets at fair market value at the conclusion of the lease term. The lease for the building and land has a term of two years with an option to buy at the end of the lease term, which the Company is reasonably certain to exercise.

~~The Company adopted the policy to not recognize ROU assets and liabilities for short term leases.~~

The components of lease cost for the Company’s leases for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 were as follows (in thousands):

Schedule of Components of Lease Cost


	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
	2020		2019		2020		2019		2021		2020		2021		2020

Operating Leases:
Lease cost	$	114	$	114	$	342	$	342	$	115	$	114	$	226	$	228

Finance Leases:
Amortization of ROU assets		109		20		161		39		58		26		117		52
Interest on lease liability		47		15		97		40		18		29		37		50
		156		35		258		79
Finance Leases										76		55		154		102

Short-term lease rent expense		3		41		7		113		3		1		6		4

Total lease cost	$	273	$	190	$	607	$	534		194		170		386		334

The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at ~~September~~June 30, ~~2020~~2021 were:

Schedule of Weighted Average Lease

	Operating Leases			Finance Leases
Weighted average remaining lease terms (years)		7.6			3.2

Weighted average discount rate		7.7	%		6.2	%

Operating Leases Finance Leases
Weighted average remaining lease terms (years) 8.2 3.4

Weighted average discount rate 8.0 % 7.9 %

The following table reconciles the undiscounted cash flows for the operating and finance leases at ~~September~~June 30, ~~2020~~2021 to the operating and finance lease liabilities recorded on the balance sheet (in thousands):

Schedule of Operating and Finance Lease Liability Maturity

	Operating Leases			Finance Leases			Operating Leases			Finance Leases
2020 Remainder	$	112		$	263
2021		450			554
2021 (Remaining)							$	211		$	353
2022		458			272			478			271
2023		466			149			486			150
2024		342			146			419			146
2025								327			146
2025 and thereafter		1,457			164			1,260			18
Total undiscounted lease payments		3,285			1,548			3,181			1,084
Less: Imputed interest		(879	)		(158	)		(787	)		(96	)
Present value of lease payments	$	2,406		$	1,390		$	2,394		$	988

Current portion of operating lease obligations	$	265		$	—
Long-term operating lease obligations, less current portion	$	2,141		$	—
Current portion of finance lease obligations	$	—		$	675
Long-term finance lease obligations, less current portion	$	—		$	715


Current portion of operating lease obligations	$	275	$	—
Long-term operating lease obligations, less current portion	$	2,119	$	—
Current portion of finance lease obligations	$	—	$	433
Long-term finance lease obligations, less current portion	$	—	$	555

Supplemental cash flow and other information related to our leases were as follows for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 (in thousands):

Three Months Ended Nine Months Ended
September 30, September 30,
2020 2019 2020 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow used in operating leases $ 111 $ 109 $ 331 $ 326
Operating cash flow used in finance leases $ 47 $ 15 $ 97 $ 40
Financing cash flow used in finance leases $ 182 $ 73 $ 411 $ 174

ROU assets obtained in exchange for lease obligations for:
Finance liabilities $ 751 $ 390 $ 874 $ 528
Operating liabilities $ — — — 182

6.	~~Intangible Assets~~

Schedule of Supplemental Cash Flow and Other Information Related to Leases


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2021		2020		2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flow used in operating leases	$	103	$	110	$	204	$	220
Operating cash flow used in finance leases	$	18	$	29	$	37	$	50
Financing cash flow used in finance leases	$	91	$	128	$	205	$	229

ROU assets obtained in exchange for lease obligations for:
Finance liabilities	$	—	$	41	$	—	$	123
Operating liabilities	$	166		—		166		—

5. Intangible Assets

The following table summarizes information relating to the Company’s definite-lived intangible assets:

Schedule of Finite-Lived Intangible Assets

																			June 30, 2021							December 31, 2020
	Weighted Average		September 30, 2020							December 31, 2019							Weighted Average Amortization		Gross					Net		Gross					Net
	Amortization		Gross					Net		Gross					Net		Period		Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying
	Period		Carrying		Accumulated			Carrying		Carrying		Accumulated			Carrying		(Years)		Amount		Amortization			Amount		Amount		Amortization			Amount
Intangibles (amount in thousands)	(Years)		Amount		Amortization			Amount		Amount		Amortization			Amount

Patent		9.7	$	785	$	(375	)	$	410	$	760	$	(358	)	$	402		12.5	$	746	$	(343	)	$	403	$	742	$	(334	)	$	408
Software		3		414		(410	)		4		414		(408	)		6		3		524		(413	)		111		418		(411	)		7
Customer relationships		10		3,370		(2,861	)		509		3,370		(2,713	)		657		10		3,370		(2,999	)		371		3,370		(2,910	)		460
Total			$	4,569	$	(3,646	)	$	923	$	4,544	$	(3,479	)	$	1,065			$	4,640	$	(3,755	)	$	885	$	4,530	$	(3,655	)	$	875

The intangible assets noted above are amortized on a straight-line basis over their useful lives with the exception of customer relationships which are being amortized using an accelerated method.

The following table summarizes the expected amortization over the next five years for our definite-lived intangible assets:

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

	Amount
Year	(In thousands)		(In thousands)

2020 (remaining)	$	56
2021		202
2021(remaining)			$	123
2022		176		198
2023		135		158
2024		13		37
2025				14

Amortization ~~expense~~expenses relating to the definite-lived intangible assets as discussed above ~~was $58,000~~were $50,000 and ~~$167,000~~$100,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and ~~$60,000~~$55,000 and ~~$194,000~~$109,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

7.	~~Capital Stock, Stock Plans and Stock-Based Compensation~~

6. Capital Stock, Stock Plans and Stock Based Compensation

The Company has certain stock option plans under which it may ~~awards~~award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants.

On ~~August 10, 2020,~~May 4, 2021, the Company granted 6,000 NQSOs from the Company’s 2003 Outside Directors Stock Plan (“2003 Plan”) to a new director elected by the Company’s Board of Directors (“Board”) to fill a vacancy on the Board. The options granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the options was ~~$7.29~~$7.50 per share, which was equal to the Company’s closing stock price per share the day preceding the grant date, pursuant to the 2003 Plan.

On July 22, 2020, the Company granted an aggregate of 12,000 NQSOs from the Company’s 2003 Plan to five of the six re-elected directors at the Company’s Annual Meeting of Stockholders held on July 22, 2020. Dr. Louis F. Centofanti, the Company’s Executive Vice President (“EVP”) of Strategic Initiatives and also a Board member, was not eligible to receive options under the 2003 Plan as an employee of the Company, pursuant to the 2003 Plan. The NQSOs granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the NQSO was $6.70 per share, which was equal to our closing stock price the day preceding the grant date, pursuant to the 2003 Plan.

On February 4, 2020, the Company granted 6,000 NQSOs from the Company’s 2003 Plan to a new director elected by the Company’s Board to fill a vacancy on the Board. The options granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the options was $7.00 per share, which was equal to the Company’s closing stock price per share the day preceding the grant date, pursuant to the 2003 Plan.

On August 29, 2019 the Company granted an aggregate of 12,500 ISOs from the 2017 Stock Option Plan (“2017 Plan”) to certain employees. The ISOs granted were for a contractual term of six years with one-fifth vesting annually over a five year period. The exercise price of the ISO was $3.90 per share, which was equal to the fair market value of the Company’s Common Stock on the date of grant.

On July 25, 2019, the Company granted an aggregate of 12,000 NQSOs from the Company’s 2003 Plan to five of the six re-elected directors at the Company’s Annual Meeting of Stockholders held on July 25, 2019. Dr. Louis F. Centofanti (a Board member) was not eligible to receive options under the 2003 Plan as an employee of the Company, pursuant to the 2003 Plan. The NQSOs granted were for a contractual term of ten years with a vesting period of six months. The exercise price of the NQSO was $3.31 per share, which was equal to our closing stock price the day preceding the grant date, pursuant to the 2003 Plan.

On January 17, 2019 the Company granted 105,000 ISOs from the 2017 Plan to certain employees, which included an aggregate of 55,000 ISOs to certain of our executive officers. The ISOs granted were for a contractual term of six years with one-fifth vesting annually over a five year period. The exercise price of the ISO was $3.15 per share, which was equal to the fair market value of the Company’s Common Stock on the date of grant.

The Company granted a NQSO to Robert Ferguson on July 27, 2017 from the Company’s 2017 Stock Option Plan (“2017 Plan”) for the purchase of up to 100,000 shares of the Company’s Common Stock (“Ferguson Stock Option”) in connection with his work as a consultant to the Company’s Test Bed Initiative (“TBI”) at our Perma-Fix Northwest Richland, Inc. (“PFNWR”) facility at an exercise price of ~~$3.65~~$3.65 per share, which was the fair market value of the Company’s Common Stock on the date of grant. The term of the Ferguson Stock Option is seven years from the grant date. The vesting of the Ferguson Stock Option is subject to the achievement of three separate milestones by certain dates. On January 17, 2019, the Company’s Compensation and Stock Option Committee (“Compensation Committee”) and Board approved an amendment to the Ferguson Stock Option whereby the vesting date for the second milestone for the purchase of up to 30,000 shares of the Company’s Common Stock was extended to March 31, 2020 from January 27, 2019. On March 27, 2020, the Compensation Committee and the Board approved another amendment to the Ferguson Stock Option whereby the vesting date for the second milestone was further extended to December 31, 2021 from March 31, 2020 and the vesting date for the third milestone for the purchase of up to 60,000 shares of the Company’s Common Stock was extended to December 31, 2022 from January 27, 2021. The 10,000 options under the first milestone were exercised by Robert Ferguson in ~~May~~ 2018. The vesting date for the second and third milestones for the purchase of up to 30,000 and 60,000 shares of the Company’s Common Stock was previously extended to December 31, 2021 and December 31, 2022, respectively. The Company has not recognized compensation costs (fair value of approximately ~~$262,000~~$262,000 at ~~September~~June 30, ~~2020)~~2021) for the remaining 90,000 Ferguson Stock Option under the remaining two milestones since achievement of the performance obligation under each of the two remaining milestones is uncertain at ~~September~~June 30, ~~2020.~~2021. All other terms of the Ferguson Stock Option remain unchanged.

The Company estimates fair value of stock options using the Black-Scholes valuation model. Assumptions used to estimate the fair value of stock options granted include the exercise price of the award, the expected term, the expected volatility of the Company’s stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and the expected annual dividend yield. The fair value of the options granted on May 4, 2021 as discussed above and the related assumptions used in the Black-Scholes option model used to value the options granted ~~for the nine months ended September 30, 2020 and 2019~~ were as follows:

Schedule of Stock Options Valuation Assumptions

		Outside Director Stock Options Granted
		May 4, 2021
Weighted-average fair value per option	$	4.97
Risk -free interest rate ⁽¹⁾		1.61	%
Expected volatility of stock ⁽²⁾		55.91	%
Dividend yield		NaN
Expected option life ⁽³⁾		10.0 years

Employee Stock Option Granted
Nine Months Ended September 30,
2019
Weighted-average fair value per share $ 1.46
Risk -free interest rate ⁽¹⁾ 1.4%-2.58 %
Expected volatility of stock ⁽²⁾ 48.67%-51.38 %
Dividend yield None
Expected option life ⁽³⁾ 5.0 years

Outside Director Stock Option Granted
Nine Months Ended September 30,
2020 2019
Weighted-average fair value per share $ 4.66 $ 2.27
Risk -free interest rate ⁽¹⁾ 0.59%-1.61 % 2.08 %
Expected volatility of stock ⁽²⁾ 55.83%-56.68 % 54.28 %
Dividend yield None None
Expected option life ⁽³⁾ 10.0 years 10.0 years

⁽¹⁾	The risk-free interest rate is based on the U.S. Treasury yield in effect at the grant date over the expected term of the option.


⁽²⁾	The expected volatility is based on historical volatility from our traded Common Stock over the expected term of the option.

⁽³⁾
⁽³⁾	The expected option life is based on historical exercises and post-vesting data.

The following table summarizes stock-based compensation recognized for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 for our employee and director stock options.

Schedule of Share-based Compensation, Allocation of Recognized Period Costs

									2021		2020		2021		2020
	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
Stock Options	September 30,				September 30,				June 30,				June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Employee Stock Options	$	34,000	$	35,000	$	99,000	$	114,000	$	33,000	$	33,000	$	66,000	$	65,000
Director Stock Options		35,000		10,000		62,000		15,000		9,000		15,000		21,000		27,000
Total	$	69,000	$	45,000	$	161,000	$	129,000	$	42,000	$	48,000	$	87,000	$	92,000
Stock-based compensation									$	42,000	$	48,000	$	87,000	$	92,000

At ~~September~~June 30, ~~2020,~~2021, the Company has approximately ~~$349,000~~$215,000 of total unrecognized compensation costs related to unvested options for employee and directors. The weighted average period over which the unrecognized compensation costs are expected to be recognized is approximately ~~2.1~~1.6 years.

The summary of the Company’s total Stock Option Plans as of ~~September~~June 30, ~~2020~~2021 and ~~September~~June 30, ~~2019,~~2020, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 Stock Option Plan, the 2017 Plans and the 2003 Plan:

Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ⁽⁴⁾
Options outstanding January 1, 2020 681,300 $ 3.84
Granted 24,000 $ 6.92
Exercised (12,500 ) $ 3.47 $ 16,060
Forfeited/expired (34,400 ) $ 5.52
Options outstanding end of period ⁽¹⁾ 658,400 $ 3.87 3.7 $ 2,096,355
Options exercisable at September 30, 2020⁽²⁾ 340,400 $ 4.01 3.6 $ 1,036,255

Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value ⁽⁴⁾
Options outstanding January 1, 2019 616,000 $ 4.23
Granted 129,500 $ 3.24
Exercised ─ $ ─
Forfeited/expired (31,800 ) $ 8.68
Options outstanding end of period ⁽³⁾ 713,700 $ 3.85 4.4 $ 611,942
Options exercisable as of September 30, 2019⁽³⁾ 299,200 $ 4.30 4.0 $ 188,082

⁽¹⁾Schedule of Stock Options ~~with exercise prices ranging from $2.79 to $7.29~~Roll Forward

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ⁽⁴⁾
Options outstanding January 1, 2021		658,400		$	3.87
Granted		6,000		$	7.50
Exercised		(500	)	$	3.15			$	2,175
Forfeited/expired		(1,500	)	$	3.15
Options outstanding end of period ⁽¹⁾		662,400		$	3.90		3.1	$	2,153,595
Options exercisable at June 30, 2021⁽²⁾		391,900		$	4.08		3.1	$	1,202,495

⁽²⁾~~Options with exercise prices ranging from $2.79 to $7.05~~

	Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ⁽⁴⁾
Options outstanding January 1, 2020		681,300		$	3.84
Granted		6,000		$	7.00				16,060
Exercised		(12,500	)	$	3.47
Forfeited/expired		(20,000	)	$	3.45
Options outstanding end of period ⁽³⁾		654,800		$	3.88		3.7	$	1,685,031
Options exercisable as of June 30, 2020⁽³⁾		306,800		$	4.20		3.6	$	711,306

⁽³⁾~~Options with exercise prices ranging from $2.79 to $13.35~~

⁽¹⁾	Options with exercise prices ranging from $2.79 to $7.50

⁽²⁾	Options with exercise prices ranging from $2.79 to $7.29

⁽³⁾	Options with exercise prices ranging from $2.79 to $8.40

⁽⁴⁾	The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price.

⁽⁴⁾~~The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price.~~

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company issued a total of ~~24,959~~26,427 shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on our Board. The Company has recorded approximately ~~$179,000~~$221,000 in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors. See “Note 15 – Subsequent Events - 2003 Plan” for a discussion of an amendment to the 2003 Plan as approved by the Company’s Stockholder at the Company’s 2021 Annual Meeting of Stockholders held on July 20, 2021.

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company issued ~~2,000 shares of its Common Stock resulting from the exercise of options from the Company’s 2017 Plan for total proceeds of $6,300. Additionally, the Company issued 1,884~~290 shares of its Common Stock from a cashless ~~exercises~~exercise of ~~8,000 and 2,500 options~~an option for the purchase of 500 shares of the Company’s Common Stock at ~~$3.60~~$3.15 per ~~share and $3.15 per share, respectively.~~share.

8.	~~Income Per Share~~

7. Income Per Share

Basic income per share is calculated based on the weighted-average number of outstanding common shares during the applicable period. Diluted income per share is based on the weighted-average number of outstanding common shares plus the weighted-average number of potential outstanding common shares. In periods where they are anti-dilutive, such amounts are excluded from the calculations of dilutive earnings per share. The following table reconciles the income ~~(loss)~~ and average share amounts used to compute both basic and diluted income per share:

Schedule of Earnings Per Share, Basic and Diluted

	Three Months Ended						Nine Months Ended
	September 30,						September 30,						Three Months Ended						Six Months Ended
(Amounts in Thousands,	(Unaudited)						(Unaudited)
Except for Per Share Amounts)	2020			2019			2020			2019
													June 30,						June 30,
Net income attributable to Perma-Fix Environmental Services, Inc., common stockholders:
													(Unaudited)						(Unaudited)
(Amounts in Thousands, Except for Per Share Amounts)													2021			2020			2021			2020
Net income (loss) attributable to Perma-Fix Environmental Services,Inc., common stockholders:
Income from continuing operations, net of taxes	$	1,481			1,895			3,049			1,719		$	3,121		$	260		$	2,083		$	1,568
Net loss attributable to non-controlling interest		(32	)		(29	)		(87	)		(90	)		(29	)		(29	)		(59	)		(55	)
Income from continuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	1,513		$	1,924		$	3,136		$	1,809			3,150			289			2,142			1,623
Loss from discontinuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders		(67	)		(156	)		(266	)		(424	)		(127	)		(85	)		(242	)		(199	)
Net income attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	1,446		$	1,768		$	2,870		$	1,385		$	3,023		$	204		$	1,900		$	1,424

Basic income per share attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	.12		$	.15		$	.24		$	.12		$	.25		$	.02		$	.16		$	.12

Diluted income per share attributable to Perma-Fix Environmental Services, Inc. common stockholders	$	.12		$	.15		$	.23		$	.11		$	.24		$	.02		$	.15		$	.12

Weighted average shares outstanding:
Basic weighted average shares outstanding		12,145			12,070			12,134			12,029			12,180			12,135			12,173			12,129
Add: dilutive effect of stock options		201			47			181			29			229			134			217			171
Add: dilutive effect of warrant		25			6			22			3
Add: dilutive effect of warrants														31			17			30			20
Diluted weighted average shares outstanding		12,371			12,123			12,337			12,061			12,440			12,286			12,420			12,320

Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include:
Potential shares excluded from above weighted average share calcualtions due to their anti-dilutive effect include:
Stock options		30			159			42			165			12			38			36			38
Warrant		—			—			—			—			—			—			—			—
Stock Options and Warrants

8. Long Term Debt

9.	~~Long Term Debt~~

Long-term debt consists of the ~~following at September 30, 2020 and December 31, 2019:~~following:

Schedule of Long term Debt

(Amounts in Thousands) September 30, 2020 December 31, 2019
Revolving Credit facility dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due on May 15, 2024. Effective interest rate for the first nine months of 2020 was 6.1%. ⁽¹⁾ $ — $ 321
Term Loan dated May 8, 2020, payable in equal monthly installments of principal, balance due on May 15, 2024. Effective interest rate for the first nine months of 2020 was 5.5%. ⁽¹⁾ 1,487 ⁽²⁾ 1,827 ⁽²⁾
Promissory Note dated April 1, 2019, payable in twelve monthly installments of interest only, starting May 1, 2019 followed with twelve monthly installments of approximately $208 in principal plus accrued interest. Interest accrues at annual rate of 4.0%. ⁽³⁾ 424 ⁽⁴⁾ 1,732 ⁽⁴⁾
Promissory Note dated April 14, 2020, subject to loan forgiveness, balance due April 14, 2022. Interest accrues at annual rate of 1.0%. ⁽³⁾ 5,318 ⁽⁵⁾ —
Note Payable dated June 10, 2020, payable in 36 monthly installments, starting in July 2020 at annual interest rate of $5.64%. 25 —
Total debt 7,254 3,880
Less current portion of long-term debt 828 ⁽⁴⁾ 1,300 ⁽⁴⁾
Long-term debt $ 6,426 $ 2,580

(Amounts in Thousands)	June 30,2021			December 31, 2020
Total debt		1,223			6,729
Revolving Credit facility dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due on May 15, 2024. Effective interest rate for the first six month of 2021 was 5.3%. ⁽¹⁾	$	—		$	—
Term Loan dated May 8, 2020, payable in equal monthly installments of principal, balance due on May 15, 2024. Effective interest rate for the first six months of 2021 was 4.4%. ⁽¹⁾		1,177	⁽²⁾		1,388	⁽²⁾
Promissory Note dated April 14, 2020, balance subject to loan forgiveness. Interest accrues at annual rate of 1.0%. ⁽³⁾		—	⁽⁴⁾		5,318	⁽⁴⁾
Notes Payable to 2023 and 2025, annual interest rate of 5.6% and 9.1%.		46			23
Total debt		1,223			6,729
Less current portion of long-term debt		404			3,595
Long-term debt	$	819		$	3,134

⁽¹⁾	Our revolving credit facility is collateralized by our accounts receivable and our term loan is collateralized by our property, plant, and equipment.

⁽²⁾	Net of debt issuance costs of ($103,000) and ($105,000) at June 30, 2021 and December 31, 2020, respectively.

⁽³⁾	Uncollateralized note.

⁽⁴⁾

Entered into with the Company’s credit facility lender under the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) (see “PPP Loan” below for information regarding forgiveness on the entire loan balance, along with accrued interest, effective June 15, 2021).

⁽¹⁾Our revolving credit facility is collateralized by our accounts receivable and our term loan is collateralized by our property, plant, and equipment. Effective July 1, 2019, monthly installment principal payment on the Term Loan was amended to approximately $35,500 from approximately $101,600. See “Revolving Credit and Term Loan Agreement” below for terms of the Company’s credit facility prior to the New Loan Agreement dated May 8, 2020.

⁽²⁾~~Net of debt issuance costs of ($113,000) and ($92,000) at September 30, 2020 and December 31, 2019, respectively.~~

⁽³⁾~~Uncollateralized note.~~

⁽⁴⁾Net of debt discount/debt issuance costs of ($99,000) and ($248,000) at September 30, 2020 and December 31, 2019, respectively. The Promissory Note provides for prepayment of principal over the term of the Note without penalty. In 2019, the Company made total prepayment of principal of $520,000 which was reflected in the current portion of the debt. During the first nine months of 2020, the Company made total principal repayment of $1,457,000 of which $416,000 was prepaid. At September 30, 2020, the outstanding balance of the loan is current.

⁽⁵⁾~~Entered into with the Company’s credit facility lender under the Paycheck Protection Program (see “PPP Loan” below for further information on this loan).~~

Revolving Credit and Term Loan Agreement

The Company entered into ana Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated ~~October 31, 2011~~May 8, 2020 (“~~Amended~~ Loan Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The ~~Amended~~ Loan Agreement ~~had been amended from time to time since the execution of the Amended Loan Agreement. The Amended Loan Agreement, as subsequently amended (“Revised Loan Agreement”), provided~~provides the Company with the following credit facility with a maturity date of March ~~24, 2021:~~15, 2024: (a) up to ~~$12,000,000~~$18,000,000 revolving credit (“revolving credit”) and (b) a term loan (“term loan”) of approximately ~~$6,100,000.~~$1,742,000, requiring monthly installments of $35,547. The maximum that the Company can borrow under the revolving credit ~~was~~is based on a percentage of eligible receivables (as defined) at any one time reduced by outstanding standby letters of credit and borrowing reductions that our lender may impose from time to time.

On May 4, 2021, the Company entered into an amendment to the Loan Agreement with its lender which provided the following, among other things:

●

revised the Company’s fixed charge coverage ratio (“FCCR”) calculation requirement which allows for the add-back of approximately $5,318,000 in eligible expenses that were incurred and covered by the PPP Loan that the Company received in 2020. The add-back is to be applied retroactively to the second and third quarters of 2020. (see below for a discussion of the PPP Loan); and

●

a capital expenditure line of up to $1,000,000with advances on the line, subject to certain limitations, permitted for up to twelve months starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during the Borrowing Period (see annual rate of interest below on the capital expenditure line). At the end of the Borrowing Period, the total amount advanced under the line will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of June 30, 2021.

In connection with the amendment, the Company paid its lender a fee of $15,000 which is being amortized over the remaining term of the Loan Agreement, as amended, as interest expense-financing fees.

~~Payment~~

Pursuant to the Loan Agreement, as amended, payment of annual rate of interest due on the revolving credit ~~under the Revised Loan Agreement was~~is at prime ~~(3.25%~~(3.25% at ~~September~~June 30, ~~2020)~~2021) plus 2% or London InterBank Offer Rate (“LIBOR”) plus 3.00% and the term loan and the capital expenditure line at prime plus ~~2.5%.~~

On May 8, 2020, the Company entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement (the “New Loan Agreement”) with PNC, replacing our previous Revised Loan Agreement with PNC. The New Loan Agreement provides the Company with the following credit facility:

	●	~~up to $18,000,000 revolving credit facility, subject to the amount of borrowings based on a percentage of eligible receivables and subject to certain reserves; and~~

	●	~~a term loan of $1,741,818, which requires monthly installments of $35,547.~~

~~The New Loan Agreement terminates as of May 15, 2024, unless sooner terminated.~~

Similar to our Revised Loan Agreement, the New Loan Agreement requires the Company to meet certain customary financial covenants, including, among other things, a minimum Tangible Adjusted Net Worth requirement of $27,000,000 at all times; maximum capital spending of $6,000,000 annually; and a minimum fixed charge coverage ratio (“FCCR”) requirement of 1.15:1.

~~Under the New Loan Agreement, payment of annual rate of interest due on the credit facility is as follows:~~

	●	~~revolving credit at prime plus 2.50% or LIBOR plus 3.50% and the term loan at prime plus 3.00% or LIBOR plus 4.00%~~2.50% or LIBOR plus 3.50%. ~~The Company can only elect to use the LIBOR interest payment option after it becomes compliant with meeting the minimum FCCR of 1.15:1; and~~

	●	Upon the achievement of a FCCR of greater than 1.25:1, the Company has the option of paying an annual rate of interest due on the revolving credit at prime plus 2.00% or LIBOR plus 3.00% and the term loan at prime plus 2.50% or LIBOR plus 3.50%. The Company met this FCCR in the first, second and third quarters of 2020. Upon meeting the FCCR of 1.25:1, this interest payment option will remain in place in the event that the Company’s future FCCR falls below 1.25:1.

Under the LIBOR option of interest payment, ~~noted above,~~ a LIBOR floor of 0.75% ~~shall apply~~applies in the event that LIBOR falls below 0.75% at any point in time.

~~Pursuant to the New Loan Agreement, the~~The Company may terminate ~~the New~~its Loan Agreement upon 90 days’ prior written notice upon payment in full of our obligations under the ~~New~~ Loan Agreement. The Company ~~has~~ agreed to pay PNC 1.0% of the total financing inhad the ~~event we pay~~Company paid off ~~our~~its obligations on or before May 7, 2021 and 0.5% of the total financing if ~~we pay~~the Company pays off ~~our~~its obligations after May 7, 2021 but prior to or on May 7, 2022. No early termination fee ~~shall~~will apply if ~~we pay~~the Company pays off ~~our~~its obligations under the ~~New~~ Loan Agreement after May 7, 2022.

In connection with New Loan Agreement, the Company paid its lender a fee of $50,000 and incurred other direct costs of approximately $35,000, which are being amortized over the term of the New Loan Agreement as interest expense-financing fees. As a result of the termination of the Revised Loan Agreement, the Company recorded approximately $27,000 in loss on extinguishment of debt in accordance with ASC 470-50, “Debt – Modifications and Extinguishment.”

At ~~September~~June 30, ~~2020,~~2021, the borrowing availability under ~~our~~the Company’s revolving credit was approximately ~~$16,404,000,~~$9,550,000 based on our eligible receivables and includes a reduction in borrowing availability of approximately ~~$3,026,000~~$3,020,000 from outstanding standby letters of credit.

The Company’s credit facility under its ~~Revised and New~~ Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under ~~our~~the credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. The Company met its ~~FCCR requirement in the first, second and third quarters of 2020. Additionally, the Company met its remaining~~ financial covenant requirements in the first ~~second~~quarter of 2021. The Company’s FCCR calculation in the first quarter of 2021 included the add-back of approximately $5,318,000 in eligible expenses that were incurred and ~~third quarters of 2020.~~

covered by the PPP Loan ~~and Securities Purchase Agreement, Promissory Note and Subordination Agreement~~

~~On April 1, 2019,~~that the Company ~~completed a lending transaction with Robert Ferguson (the “Lender”), whereby~~received in 2020 as permitted by the ~~Company borrowed from the Lender the sum of $2,500,000 pursuant~~amendment dated May 4, 2021 to the ~~terms of a~~Company’s Loan ~~and Security Purchase~~ Agreement ~~and promissory note (the “Loan”).~~as discussed above. The ~~Lender is a shareholder of the~~ Company ~~and also serves as a consultant to the Company in connection with the Company’s TBI at~~did not meet its PFNWR subsidiary. The proceeds from the Loan were used for general working capital purposes. The Loan is unsecured, with a term of two years with interest payable at a fixed interest rate of 4.00% per annum. The Loan provides for monthly payments of accrued interest only during the first year of the Loan, with the first interest payment due May 1, 2019 and monthly payments of approximately $208,333 in principal plus accrued interest startingFCCR requirement in the second ~~year~~quarter of 2021. However, this FCCR non-compliance was waived by the ~~Loan. The Loan also allows for prepayment of principal payments over the term of the Loan without penalty with such prepayment of principal payments~~Company’s lender pursuant to ~~be applied~~another amendment dated August 10, 2021 to the ~~second year of the loan payments at the~~ Company’s ~~discretion. Since inception of the loan, the Company has made total prepayments in principal of $936,000, of which $416,000 was made in the first nine months of 2020. In connection with the above~~ Loan ~~the Lender agreed under the terms of the Loan and a Subordination~~ Agreement with our credit facility lender, to subordinate payment under the Loan, and agreed that the Loan will be junior in right of payment to the credit facility in the event of default or bankruptcy or other insolvency proceeding by us. In connection with this capital raise transaction described above and consideration for us receiving the Loan, the Company issued a Warrant (the “Warrant”) to the Lender to purchase up to 60,000 shares of our Common Stock at an exercise price of $3.51 per share, which was the closing bid price(see “Note 15 – Subsequent Events – Credit Facility” for a share of our Common Stock on NASDAQ.com immediately preceding the execution of the Loan and Warrant. The Warrant expires on April 1, 2024 and remains outstanding at September 30, 2020. As further consideration for this capital raise transaction relating to the Loan, the Company also issued 75,000 shares of its Common Stock to the Lender. The fair value of the Warrant and Common Stock and the related closing fees incurred from the transaction totaled approximately $398,000 and was recorded as debt discount/debt issuance costs, which is being amortized over the term of the loan as interest expense – financing fees. The 75,000 shares of Common Stock, the Warrant and the 60,000 shares of Common Stock that may be purchased under the Warrant were and will be issued in a private placement that was and will be exempt from registration under Rule 506 and/or Sections 4(a)(2) and 4(a)(5) of the Securities Act of 1933, as amended (the “Act”) and bear a restrictive legend against resale except in a transaction registered under the Act or in a transaction exempt from registration thereunder.

Upon default, the Lender will have the right to elect to receive in full and complete satisfaction of the Company’s obligations under the Loan either: (a) the cash amount equal to the sum of the unpaid principal balance owing under the loan and all accrued and unpaid interest thereon (the “Payoff Amount”) or (b) upon meeting certain conditions, the number of whole shares of the Company’s Common Stock (the “Payoff Shares”) determined by dividing the Payoff Amount by the dollar amount equal to the closing bid price of our Common Stock on the date immediately prior to the date of default, as reported or quoted on the primary nationally recognized exchange or automated quotation system on which our Common Stock is listed; provided however, that the dollar amount of such closing bid price shall not be less than $3.51, the closing bid price for our Common Stock as disclosed on NASDAQ.com immediately preceding the signingdiscussion of this ~~loan agreement.~~waiver and additional provisions of this amendment).

If issued, the Payoff Shares will not be registered and the Lender will not be entitled to registration rights with respect to the Payoff Shares. The aggregate number of shares, warrant shares, and Payoff Shares that are or will be issued to the Lender pursuant to the Loan, together with the aggregate shares of the Company’s Common Stock and other voting securities of the Company owned by the Lender or which may be acquired by the Lender as of the date of issuance of the Payoff Shares, shall not exceed the number of shares of the Company’s Common Stock equal to 14.9% of the number of shares of the Company’s Common Stock issued and outstanding as of the date immediately prior to the default, less the number of shares of the Company’s Common Stock owned by the Lender immediately prior to the date of such default plus the number of shares of our Common Stock that may be acquired by the Lender under warrants and/or options outstanding immediately prior to the date of such default.

PPP Loan

On April 14, 2020, the Company entered into a promissory note under the PPP with PNC, our credit facility lender, ~~in the amount~~which had a balance of approximately ~~$5,666,000 (“PPP~~$5,318,000 (the “PPP Loan”) ~~under the PPP.~~at March 31, 2021. The PPP was established under the CARES Act and is administered by the U.S. Small Business Administration (“SBA”). ~~On June 5, 2020,~~The CARES Act was subsequently amended by the Paycheck Protection Program Flexibility Act ~~was signed into law which amended the CARES Act. The note evidencing the PPP Loan contains events~~ of ~~default relating to, among other things, payment defaults, breach of representations and warranties, and provisions of~~2020 (“Flexibility Act”). Proceeds from the promissory ~~note. During the third quarter of 2020, the Company repaid approximately $348,000 of the PPP Loan to PNC resulting from clarification made in the loan calculation at the time of the loan origination.~~

Under the terms of the Flexibility Act, the Company can apply for and be granted forgiveness for all or a portion of the PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of loan proceedsnote was used by the Company for eligible payroll costs, mortgage interest, rent and utility costs ~~and~~as permitted under the ~~maintenance of employee and compensation levels for the covered period (which is defined as a 24 week period, beginning April 14, 2020, the date in which proceeds from~~Flexibility Act. The annual interest rate on the PPP Loan ~~was disbursed to the Company by PNC). At least 60% of such forgiven amount must be used for eligible payroll costs.~~ is 1.0%

On October 5, 2020, the Company applied for forgiveness on repayment of the ~~loan balance~~PPP Loan as permitted under the ~~program, which is subject to~~Flexibility Act. On July 1, 2021, the ~~review and approval of our lender and~~Company was notified by PNC that the ~~SBA. The approval of the loan forgiveness allows for a maximum period of 150 days from the submittal of a complete loan forgiveness application. If all or a portion~~entire balance of the PPP Loan ~~is not~~of approximately $5,318,000, along with accrued interest of approximately $63,000 was forgiven ~~all or~~by the ~~remaining portion of~~SBA, effective June 15, 2021. Accordingly, the ~~loan will be for a term of two years but can be prepaid at any time prior to maturity without any prepayment penalties. The annual interest rate on~~Company recorded the entire forgiven PPP Loan ~~is 1.0%~~balance, along with accrued interest, totaling approximately $5,381,000 as “Gain on extinguishment of debt” on its Consolidated Statement of Operations for the quarter ended June 30, 2021.

9. Commitments and no payments of principal or interest are due until the date that the SBA remits the loan forgiveness amount to our lender. While the Company’s PPP Loan currently has a two year maturity, the Flexibility Act permits the Company to request a five year maturity with our lender which the Company does not expect to request at this time.Contingencies

~~10.~~

~~Commitments and Contingencies~~

Hazardous Waste

In connection with our waste management services, ~~we process~~the Company processes both hazardous and non-hazardous waste, which we transport to our own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required weat the disposal site, the Company could be a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.

Legal Matters

In the normal course of conducting our business, we are involved in various litigation. We are not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that could would have a material adverse effect on our financial position, liquidity or results of future operations.

During July 2020, Tetra Tech EC, Inc. (“Tetra Tech”) filed a complaint in the United States District Court for the Northern District of California (the “Court”) against CH2M Hill, Inc. (“CH2M”) and four subcontractors of CH2M, including the Company (“~~defendants”~~Defendants”). The complaint alleges claims for negligence, negligent misrepresentation and equitable indemnification against all defendants related to alleged damages suffered by Tetra Tech in respect of certain draft reports prepared by defendants at the request of the U.S. Navy as part of an investigation and review of certain whistleblower complaints about Tetra Tech’s environmental restoration at the Hunter’s Point Naval Shipyard in San Francisco.

CH2M was hired by the Navy in 2016 to review Tetra Tech’s work. CH2M subcontracted with environmental consulting and cleanup firms Battelle Memorial Institute, Cabrera Services, Inc., SC&A, Inc. and the Company to assist with the review, according to the complaint.

The complaint alleges that the subject draft reports were prepared negligently and in a biased manner, made public, and caused damage to Tetra Tech’s reputation; triggering related lawsuits and costing it opportunities for both government and commercial contracts.

~~At this time, the Company does not believe it has any liability to Tetra Tech.~~ The Company has provided notice of this lawsuit to our insurance carrier. Our insurance carrier is providing a defense on our behalf in connection with this lawsuit, subject to a ~~$100,000~~$100,000 self-insured retention and the terms and limitations contained in the insurance policy.

~~Insurance~~On January 7, 2021, Defendants’ motion to dismiss the complaint in its entirety was granted without prejudice, with leave to amend. Tetra Tech subsequently filed a First Amended Complaint (“FAC”) and Defendants filed a motion to dismiss Tetra Tech’s FAC. Tetra Tech filed an opposition to Defendant’s motion to dismiss Tetra Tech’s FAC. Defendants, subsequently filed a joint reply to Tetra Tech’s motion in opposition. A decision and Order on Defendants’ motion to dismiss is pending from the Court. At this time, the Company continues to believe it does not have any liability to Tetra Tech.

Insurance

The Company has a ~~25-year~~25-year finite risk insurance policy entered into in June 2003 (“2003 Closure Policy”) with AIG Specialty Insurance Company (“AIG”), which provides financial assurance to the applicable states for our permitted facilities in the event of unforeseen closure. The 2003 Closure Policy, as amended, provides for a maximum allowable coverage of ~~$28,177,000~~$28,177,000 which includes available capacity to allow for annual inflation and other performance and surety bond requirements. Total coverage under the 2003 Closure Policy, as amended, was ~~$19,651,000~~$19,898,000 at ~~September~~June 30, ~~2020.~~2021. At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, finite risk sinking funds contributed by the Company related to the 2003 Closure Policy which is included in other long term assets on the accompanying Consolidated Balance Sheets totaled ~~$11,418,000~~$11,467,000 and ~~$11,307,000,~~$11,446,000, respectively, which included interest earned of ~~$1,947,000~~$1,996,000 and ~~$1,836,000~~$1,975,000 on the finite risk sinking funds as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. Interest income for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 was approximately ~~$28,000~~$2,000 and ~~$111,000,~~$21,000, respectively. Interest income for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 was approximately ~~$77,000~~$27,000 and ~~$265,000,~~$83,000, respectively. If ~~the Company~~we so ~~elects,~~elect, AIG is obligated to pay usthe Company an amount equal to 100% of the finite risk sinking fund account balance in return for complete release of liability from both usthe Company and any applicable regulatory agency using this policy as an instrument to comply with financial assurance requirements.

Letter of Credits and Bonding Requirements

From time to time, the Company is required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. At ~~September~~June 30, ~~2020,~~2021, the total amount of standby letters of credit outstanding was approximately ~~$3,026,000~~$3,020,000 and the total amount of bonds outstanding was approximately ~~$45,814,000.~~$43,561,000.

~~11.~~

~~Discontinued Operations~~

10. Discontinued Operations

The Company’s discontinued operations consist of all our subsidiaries included in our previous Industrial Segment which encompasses subsidiaries divested in 2011 and prior and three previously closed locations.

The Company’s discontinued operations had net losses of ~~$67,000~~$127,000 and ~~$156,000~~$85,000 for the three months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively (net of taxes of $0$0 for each period) and net losses of ~~$266,000~~$242,000 and ~~$424,000~~$199,000 for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively, (net of taxes of $0$0 for each period). The losses were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations. The Company’s discontinued operations had no revenues for ~~any~~each of the periods noted above.

The following table presents the major class of assets of discontinued operations ~~at September~~as of June 30, ~~2020~~2021 and December 31, ~~2019.~~2020. No assets and liabilities were held for sale at each of the periods noted.

September 30, December 31,
(Amounts in Thousands) 2020 2019
Current assets
Other assets $ 17 $ 104
Total current assets 17 104
Long-term assets
Property, plant and equipment, net ⁽¹⁾ 81 81
Other assets — 36
Total long-term assets 81 117
Total assets $ 98 $ 221
Current liabilities
Accounts payable $ 8 $ 8
Accrued expenses and other liabilities 167 169
Environmental liabilities 744 817
Total current liabilities 919 994
Long-term liabilities
Closure liabilities 140 134
Environmental liabilities 110 110
Total long-term liabilities 250 244
Total liabilities $ 1,169 $ 1,238

⁽¹⁾~~net~~Schedule of ~~accumulated depreciation of $10,000 for each period presented.~~Disposal Groups, Including Discontinued Operation Balance Sheet

	June 30,		December 31,
(Amounts in Thousands)	2021		2020
Current assets
Other assets	$	17	$	22
Total current assets		17		22
Long-term assets
Property, plant and equipment, net ⁽¹⁾		81		81
Other assets		—		—
Total long-term assets		81		81
Total assets	$	98	$	103
Current liabilities
Accounts payable	$	4	$	4
Accrued expenses and other liabilities		142		150
Environmental liabilities		671		744
Total current liabilities		817		898
Long-term liabilities
Closure liabilities		146		142
Environmental liabilities		110		110
Total long-term liabilities		256		252
Total liabilities	$	1,073	$	1,150

The Company’s discontinued operations included a note receivable in the original amount of approximately $375,000 recorded in May 2016 resulting from the sale of property at our Perma-Fix of Michigan, Inc. (“PFMI”) subsidiary. This note required 60 equal monthly installment payments by the buyer of approximately $7,250 (which includes interest). On July 24, 2020, the purchaser of the property paid off the outstanding note receivable balance of approximately $105,000.

~~12.~~⁽¹⁾

~~Operating Segments~~net of accumulated depreciation of $10,000 for each period presented.

11. Operating Segments

In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.

Our reporting segments are defined as below:

TREATMENT SEGMENT, which includes:

	●-	nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through ~~three~~four uniquely licensed and permitted treatment and storage facilities; and
	●
	-	Research & Development (“R&D&D”) activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.

SERVICES SEGMENT, which includes:

●-

Technical services, which include:

	○	professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
	○	health physics services including health physicists, radiological engineers, nuclear engineers and health physics technicians support to government and private radioactive materials licensees;
	○	integrated Occupational Safety and Health services including IHindustrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and ~~OSHA~~Occupational Safety and Health Administration (“OSHA”) citation assistance;

24○

	○	global technical services providing consulting, engineering (civil, nuclear, mechanical, chemical, radiological and environmental), project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
	○	~~on-site~~ waste management services to commercial and governmental customers.

●-

Nuclear services, which include:

	○	~~technology-based services including engineering,~~ decontamination and decommissioning (“D&D”), of government and commercial facilities impacted with radioactive material and hazardous constituents including engineering, technology applications, specialty services, ~~and construction,~~ logistics, transportation, processing and disposal;
	○	~~remediation~~license termination support of ~~nuclear~~radioactive material licensed and federal facilities over the entire cycle of the termination process: project management, planning, characterization, waste stream identification and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation;delineation, remediation/demo, final status survey, compliance demonstration, reporting, transportation, disposal and emergency ~~response; and~~response.

	●-	A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized ~~NIOSH~~nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.
	●-	A company owned gamma spectroscopy laboratory for the analysis of oil and gas industry solids and liquids.

MEDICAL SEGMENT, which ~~includes:~~is currently involved on a limited basis in the R&D of the Company’s medical isotope production technology, ~~by our majority-owned Polish subsidiary, Perma-Fix of Medical or the Medical Segment. The Medical Segment~~ has not generated any ~~revenues~~revenue and ~~all costs incurred are reflected within R&D in the accompanying consolidated financial statements. As previously disclosed, the Medical Segment~~ has substantially reduced its R&D costs and activities due to the need for capital to fund these activities. The Company anticipates that the Medical Segment will not resume full R&D activities until the necessary capital is obtained through its own credit facility or additional equity raise, or obtains partners willing to provide funding for its R&D.

Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 1110 – Discontinued Operations”) which do not generate revenues.

The table below presents certain financial information of our operating segments for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 (in thousands).:

Schedule of Segment Reporting Information

Segment Reporting for the Quarter Ended ~~September~~June 30, ~~2020~~2021

		Treatment		Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	7,706		$	8,439			—		$	16,145		$	—		$	16,145
Intercompany revenues		319			32			—			351			—			—
Gross profit (negative gross profit)		1,433			(467	)		—			966			—			966
Research and development		43			19			72			134			10			144
Interest income		—			—			—			—			2			2
Interest expense		(18	)		—			—			(18	)		(47	)		(65	)
Interest expense-financing fees		—			—			—			—			(9	)		(9	)
Depreciation and amortization		310			85			—			395			5			400
Segment income (loss) before income taxes		471			(1,292	)		(72	)		(893	)		4,027	⁽²⁾		3,134
Income tax expense		3			10			—			13			—			13
Segment income (loss)		468			(1,302	)		(72	)		(906	)		4,027			3,121
Expenditures for segment assets		270			10			—			280			9			289	⁽³⁾

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 7,066 $ 23,106 — $ 30,172 $ — $ 30,172
Intercompany revenues 226 6 — 232 — —
Gross profit 1,094 3,656 — 4,750 — 4,750
Research and development 49 7 81 137 20 157
Interest income — — — — 28 28
Interest expense (34 ) (3 ) — (37 ) (50 ) (87 )
Interest expense-financing fees — — — — (58 ) (58 )
Depreciation and amortization 373 97 — 470 8 478
Segment income (loss) before income taxes 280 2,813 (81 ) 3,012 (1,664 ) 1,348
Income tax (benefit) expense (170 ) 2 — (168 ) 35 (133 )
Segment income (loss) 450 2,811 (81 ) 3,180 (1,699 ) 1,481
Expenditures for segment assets 95 24 — 119 3 122 ⁽²⁾

Segment Reporting for the Quarter Ended ~~September~~June 30, ~~2019~~2020

		Treatment		Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	7,840		$	14,207			—		$	22,047		$	—		$	22,047
Intercompany revenues		446			5			—			451			—			—
Gross profit		1,695			1,615			—			3,310			—			3,310
Research and development		52			46			74			172			37			209
Interest income		1			—			—			1			27			28
Interest expense		(28	)		(4	)		—			(32	)		(67	)		(99	)
Interest expense-financing fees		—			—			—			—			(60	)		(60	)
Depreciation and amortization		275			84			—			359			5			364
Segment income (loss) before income taxes		750			1,031			(74	)		1,707			(1,456	)		251
Income tax benefit		(9	)		—			—			(9	)		—			(9	)
Segment income (loss)		759			1,031			(74	)		1,716			(1,456	)		260
Expenditures for segment assets		320			146			—			466			2			468	⁽⁴⁾

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 10,081 $ 12,454 — $ 22,535 $ — $ 22,535
Intercompany revenues 75 38 — 113 — —
Gross profit 3,338 1,819 — 5,157 — 5,157
Research and development 85 — 74 159 6 165
Interest income — — — — 77 77
Interest expense (19 ) (5 ) — (24 ) (75 ) (99 )
Interest expense-financing fees — — — — (69 ) (69 )
Depreciation and amortization 243 79 — 322 6 328
Segment income (loss) before income taxes 2,244 1,193 (74 ) 3,363 (1,413 ) 1,950
Income tax expense 55 — — 55 — 55
Segment income (loss) 2,189 1,193 (74 ) 3,308 (1,413 ) 1,895
Expenditures for segment assets 470 31 — 501 — 501 ⁽³⁾

Segment Reporting for the ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021

		Treatment		Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	15,201		$	24,077			—		$	39,278		$	—		$	39,278
Intercompany revenues		979			39			—			1,018			—			—
Gross profit		2,358			964			—			3,322			—			3,322
Research and development		90			32			149			271			24			295
Interest income		—			—			—			—			21			21
Interest expense		(37	)		(8	)		—			(45	)		(87	)		(132	)
Interest expense-financing fees		—			—			—			—			(17	)		(17	)
Depreciation and amortization		620			170			—			790			9			799
Segment income (loss) before income taxes		352			(737	)		(149	)		(534	)		2,613	⁽²⁾		2,079
Income tax (benefit) expense		(14	)		10			—			(4	)		—			(4	)
Segment income (loss)		366			(747	)		(149	)		(530	)		2,613			2,083
Expenditures for segment assets		627			14			—			641			9			650	⁽³⁾

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 24,469 $ 52,610 — $ 77,079 $ — $ 77,079
Intercompany revenues 879 19 — 898 — —
Gross profit 5,533 7,167 — 12,700 — 12,700
Research and development 194 119 221 534 64 598
Interest income 1 — — 1 111 112
Interest expense (80 ) (13 ) — (93 ) (213 ) (306 )
Interest expense-financing fees — — — — (187 ) (187 )
Depreciation and amortization 912 259 — 1,171 18 1,189
Segment income (loss) before income taxes 2,577 5,162 (221 ) 7,518 (4,597 ) 2,921
Income tax (benefit) expense (165 ) 2 — (163 ) 35 (128 )
Segment income (loss) 2,742 5,160 (221 ) 7,681 (4,632 ) 3,049
Expenditures for segment assets 1,095 385 — 1,480 8 1,488 ⁽²⁾

Segment Reporting for the ~~Nine~~Six Months Ended ~~September~~June 30, ~~2019~~2020

		Treatment		Services			Medical			Segments Total			Corporate ⁽¹⁾			Consolidated Total
Revenue from external customers	$	17,403		$	29,504			—		$	46,907		$	—		$	46,907
Intercompany revenues		653			13			—			666			—			—
Gross profit		4,440			3,510			—			7,950			—			7,950
Research and development		145			112			140			397			44			441
Interest income		1			—			—			1			83			84
Interest expense		(46	)		(10	)		—			(56	)		(163	)		(219	)
Interest expense-financing fees		—			—			—			—			(129	)		(129	)
Depreciation and amortization		539			162			—			701			10			711
Segment income (loss) before income taxes		2,297			2,349			(140	)		4,506			(2,933	)		1,573
Income tax expense		5			—			—			5			—			5
Segment income (loss)		2,292			2,349			(140	)		4,501			(2,933	)		1,568
Expenditures for segment assets		1,000			361			—			1,361			5			1,366	⁽⁴⁾

Treatment Services Medical Segments Total Corporate ⁽¹⁾ Consolidated Total
Revenue from external customers $ 30,079 $ 21,299 — $ 51,378 $ — $ 51,378
Intercompany revenues 83 101 — 184 — —
Gross profit 8,921 2,008 — 10,929 — 10,929
Research and development 367 — 228 595 20 615
Interest income — — — — 265 265
Interest expense (66 ) (18 ) — (84 ) (209 ) (293 )
Interest expense-financing fees — — — — (139 ) (139 )
Depreciation and amortization 713 236 — 949 19 968
Segment income (loss) before income taxes 5,731 318 (228 ) 5,821 (4,003 ) 1,818
Income tax expense 99 — — 99 — 99
Segment income (loss) 5,632 318 (228 ) 5,722 (4,003 ) 1,719
Expenditures for segment assets 764 49 — 813 — 813 ⁽³⁾

⁽¹⁾	Amounts reflect the activity for corporate headquarters not included in the segment information.


⁽²⁾	Amounts includes approximately $5,381,000 of “Gain on extinguishment of debt” recorded in connection with the Company’s PPP Loan which was forgiven by the SBA effective June 15, 2021 (see “Note 8 – Long Term Debt – PPP Loan” for information of this loan forgiveness).

⁽³⁾	Net of financed amount of ~~$751,000~~$0 and ~~$883,000~~$29,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively.

⁽⁴⁾
⁽³⁾	Net of financed amount of ~~$6,000~~$51,000 and ~~$29,000~~$132,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

12. Income Taxes

~~13.~~

~~Income Taxes~~

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes.

The Company had anincome tax expense of $13,000 and income tax benefit of ~~$133,000 and income tax expense of $55,000~~$4,000 for continuing operations for the three and six months ended ~~September~~June 30, ~~2020 and 2019,~~2021, respectively, and an income tax benefit of ~~$128,000~~$9,000 and income tax expense of ~~$99,000~~$5,000 for continuing operations for the ~~nine~~three and six months ended ~~September~~June 30, 2020, ~~and 2019,~~ respectively. ~~Our~~The Company’s effective tax rates were approximately ~~9.9%~~0.4% and ~~2.8%~~0.2% for the three and six months ended ~~September~~June 30, 2021, respectively, and 3.6% and 0.3% for the three and six months ended June 30, 2020, ~~and 2019, respectively, and 4.4% and 5.4% for the nine months ended September 30, 2020 and 2019,~~ respectively. ~~The tax benefit and expense for the periods above were comprised of state tax benefit and expense for separate company filing states.~~ The Company’s tax rate for each of the periods discussed above was impacted by the Company’s full valuation on its net deferred tax assets. ~~The income tax benefit for the three and nine months ended September 30, 2020 included refunds from amended state returns filed in separate company filing states.~~

~~14.~~

~~Variable Interest Entities (“VIE”)~~

~~On May 24, 2019, the~~13. Variable Interest Entities (“VIE”)

The Company and Engineering/Remediation Resources Group, Inc. (“ERRG”) previously entered into an unpopulated joint venture agreement for project work bids within the Company’s Services ~~Segment. The~~Segment with the joint venture is doing business as Perma-Fix ERRG, a general partnership. The Company has a 51% partnership interest in the joint venture and ERRG has a 49% partnership interest in the joint venture. ~~Activities under Perma-Fix ERRG did not commence until the first quarter of 2020.~~

The Company determines whether joint ventures in which it has invested meet the criteria of a VIE at the start of each new venture and when a reconsideration event has occurred. A VIE is a legal entity that satisfies any of the following characteristics: (a) the legal entity does not have sufficient equity investment at risk; (b) the equity investors at risk as a group, lack the characteristics of a controlling financial interest; or (c) the legal entity is structured with disproportionate voting rights.

The Company consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

Based on the Company’s evaluation of Perma-Fix ERRG and related agreements with Perma-Fix ERRG, the Company determined that Perma-Fix ERRG iscontinues to be a VIE in which ~~we are~~the Company is the primary beneficiary. At ~~September~~June 30, ~~2020,~~2021, Perma-Fix ERRG had total assets of ~~$5,302,000~~$2,528,000 and total liabilities of ~~$5,302,000~~$2,528,000 which are all recorded as current.

~~15.~~

~~Deferral of Employment Tax Deposits~~

14. Deferral of Employment Tax Deposits

The ~~CARES Act, as amended by the~~ Flexibility Act ~~which was signed into law on June 5, 2020,~~ provides employers the option to defer the payment of an employer’s share of social security taxes beginning on March 27, 2020 through December 31, 2020 with 50% of the amount of social security taxes deferred to become due on December 31, 2021 with the remaining 50% due on December 31, 2022. The Company elected to defer such taxes starting in mid-April 2020. ~~The Company estimates the remaining payment of approximately $1,225,000 of social security taxes otherwise due in 2020 will be deferred with 50% due by December 31,~~At June 30, 2021, ~~and the remaining 50% due by December 31, 2022. At September 30, 2020,~~ the Company has deferred payment of approximately ~~$838,000~~$1,252,000 in its share of social security taxes, of which ~~amount has been~~approximately $626,000 is included in ~~“other~~“Other long-term ~~liabilities”~~liabilities,” with the remaining balance included in “Accrued expenses” within current liabilities in the Company’s Consolidated Balance ~~Sheet at September 30, 2020.~~Sheets.

~~16.~~

~~Employment Agreements and Management Incentive Plan (“MIP”)~~

~~On July 22, 2020,~~15. Subsequent Events

Management evaluated events occurring subsequent to June 30, 2021 through August 11, 2021, the date these consolidated financial statements were available for issuance, and other than as noted below determined that no material recognizable subsequent events occurred.

2003 Plan

During April 2021, the Company’s Board ~~appointed Richard Grondin~~approved an amendment to the ~~position~~2003 Plan which was approved by the Company’s Shareholders at the Company’s Annual Meeting of Stockholders held on July 20, 2021 (the “Meeting”). The amendment provides, among other things, the following:

	●	The number of shares of Common Stock available for issuance under the 2003 Plan was increased by an additional 500,000 shares;
	●	Each outside director is to be granted an option to purchase up to 10,000 shares of Common Stock on each date the director is reelected to the Board;
	●	Each newly-elected outside director is to be granted an option to purchase up to 20,000 shares of Common Stock upon initial election to the Board; and
	●	Changes to the vesting schedule of each option granted under the 2003 Plan to outside directors.

Upon the approval of the amendment to the 2003 Plan as discussed above and upon the reelection of the Company’s seven outside directors at the Meeting, the Company issued a NQSO to each of the Company’s seven reelected outside directors for the purchase of up to 10,000 shares of the Company’s Common Stock. Dr. Louis Centofanti, the Company’s EVP of ~~Waste Treatment Operations~~Strategic Initiatives and also a director, was not eligible to receive an ~~executive officer~~option under the 2003 Plan as an employee of the Company. ~~Mr. Grondin previously held~~Each NQSO granted was for a contractual term of ten years with one-fourth vesting annually over a four year period. The exercise price of the ~~position of Vice President of Western Operations within our Treatment Segment. Immediately after the appointment of Richard Grondin~~NQSO was $5.93 per share, which was equal to the ~~position of EVP of Waste Treatment Operations and an executive officer~~fair market value of the ~~Company,~~Company’s Common Stock the ~~Company’s Compensation Committee and~~day preceding the ~~Board approved, and~~grant date, pursuant to the 2003 Plan.

Credit Facility

On August 10, 2021, the Company entered into an ~~employment agreement~~amendment to its Loan Agreement with each of Mark Duff, CEO (the “CEO Employment Agreement”), Dr. Louis Centofanti, EVP of Strategic Initiatives (the “EVP of Strategic Initiatives Employment Agreement”), Ben Naccarato, CFO (the “CFO Employment Agreement”), Andrew Lombardo, EVP of Nuclear and Technical Services (the “EVP of Nuclear and Technical Services Employment Agreement”), and Richard Grondin, EVP of Waste Treatment Operations (the “EVP of Waste Treatment Operations Employment Agreement”), collectivelyits lender which provided, among other things, the following:

	●	waived the Company’s failure to meet the minimum quarterly FCCR requirement for the second quarter of 2021;
	●	removes the quarterly FCCR testing requirement for the third quarter of 2021;
	●	reinstates the quarterly FCCR testing requirement starting for the fourth quarter of 2021 and revises the methodology to be used in calculating the FCCR for the quarters ending December 31, 2021, March 31, 2022, and June 30, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter); and
	●	requires maintenance of a minimum $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended December 31, 2021 has been met and certified to the lender.

In connection with the CEO Employment Agreement, the EVP of Strategic Initiative Employment Agreement, the CFO Employment Agreement, the EVP of Nuclear and Technical Services Employment Agreement and the EVP of Waste Treatment Operations Employment Agreement, the “New Employment Agreements” and each individually the “New Employment Agreement”. The Company had previously entered into an employment agreement with each of Mark Duff, Dr. Louis Centofanti and Ben Naccarato on September 8, 2017, all three of which were due to expire on September 8, 2020. These three employment agreements dated September 8, 2017 were terminated effective July, 22, 2020.

Pursuant to New Employment Agreements, which are effective July 22, 2020, each of these executive officers is provided an annual salary, which annual salary may be increased, but not reduced, from time to time as determined by the Compensation Committee. As a result of Richard Grondin’s promotion to EVP of Waste Treatment and an executive officer ofamendment, the Company ~~his annual salary was increased from $208,000 as Vice President~~paid its lender a fee of Western Operations within our Treatment Segment to $240,000, effective July 22, 2020. No change was made to the salary of the remaining executive officers for fiscal year 2020. In addition, each of these executive officers is entitled to participate in the Company’s broad-based benefits plans and to certain performance compensation payable under separate Management Incentive Plans (“MIP”) as approved by the Company’s Compensation Committee and the Company’s Board. The Company’s Compensation Committee and the Board approved individual 2020 MIP on January 16, 2020 (which are effective January 1, 2020) for each Mark Duff, Dr. Louis Centofanti, Ben Naccarato and Andrew Lombardo which remains effective for fiscal year 2020. See “MIP” below for the MIP approved by the Compensation Committee and the Board for Richard Grondin.

Each of the New Employment Agreements is effective for three years from July 22, 2020 (the “Initial Term”) unless earlier terminated by the Company or by the executive officer. At the end of the Initial Term of each New Employment Agreement, each New Employment Agreement will automatically be extended for one additional year, unless at least six months prior to the expiration of the Initial Term, the Company or the executive officer provides written notice not to extend the$15,000. All other terms of the ~~New Employment Agreement.~~Loan Agreement remains principally unchanged.

Pursuant to the New Employment Agreements, if the executive officer’s employment is terminated due to death/disability or for cause (as defined in the agreements), the Company will pay to the executive officer or to his estate an amount equal to the sum of any unpaid base salary and accrued unused vacation time through the date of termination and any benefits due to the executive officer under any employee benefit plan (the “Accrued Amounts”) plus any performance compensation payable pursuant to the MIP with respect to the fiscal year immediately preceding the date of termination.

If the executive officer terminates his employment for “good reason” (as defined in the agreements) or is terminated by the Company without cause (including any such termination for “good reason” or without cause within 24 months after a Change in Control (as defined in the agreement)), the Company will pay the executive officer the Accrued Amounts, two years of full base salary, and two times the performance compensation (under the MIP) earned with respect to the fiscal year immediately preceding the date of termination provided the performance compensation earned with respect to the fiscal year immediately preceding the date of termination has not been paid. If performance compensation earned with respect to the fiscal year immediately preceding the date of termination has been made to the executive officer, the executive officer will be paid an additional year of the performance compensation earned with respect to the fiscal year immediately preceding the date of termination. If the executive terminates his employment for a reason other than for good reason, the Company will pay to the executive an amount equal to the Accrued Amounts plus any performance compensation payable pursuant to the MIP with respect to the fiscal year immediately preceding the date of termination.

If there is a Change in Control (as defined in the agreements), all outstanding stock options to purchase common stock held by the executive officer will immediately become exercisable in full commencing on the date of termination through the original term of the options. In the event of the death of an executive officer, all outstanding stock options to purchase common stock held by the executive officer will immediately become exercisable in full commencing on the date of death, with such options exercisable for the lesser of the original option term or twelve months from the date of the executive officer’s death. In the event an executive officer terminates his employment for “good reason” or is terminated by the Company without cause, all outstanding stock options to purchase common stock held by the executive officer will immediately become exercisable in full commencing on the date of termination, with such options exercisable for the lesser of the original option term or within 60 days from the date of the executive’s date of termination. Severance benefits payable with respect to a termination (other than Accrued Amounts) shall not be payable until the termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h)).

On July 22, 2020, upon the approval of the EVP of Waste Treatment Operations Employment Agreement as discussed above, the Company’s Board and the Company’s Compensation Committee approved a MIP for Richard Grondin effective January 1, 2020, applicable for fiscal 2020. The MIP provides guidelines for the calculation of annual cash incentive-based compensation, subject to Compensation Committee oversight and modification. The MIP awards cash compensation based on achievement of performance thresholds, with the amount of such compensation established as a percentage of the Mr. Grondin’s 2020 annual base salary as the EVP of Waste Treatment Operations. The potential target performance compensation ranges from 5% to 100% ($12,000 to $240,000) of the base salary for the EVP of Waste Treatment Operations, which became effective on July 22, 2020.

~~Item 2.~~

~~Management’s Discussion and Analysis of Financial Condition and Results of Operations~~

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Statements

Certain statements contained within this report may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, the “Private Securities Litigation Reform Act of 1995”). All statements in this report other than a statement of historical fact are forward-looking statements that are subject to known and unknown risks, uncertainties and other factors, which could cause actual results and performance of the Company to differ materially from such statements. The words “believe,” “expect,” “anticipate,” “intend,” “will,” and similar expressions identify forward-looking statements. Forward-looking statements contained herein relate to, among other things,

●	demand for our services;
●	reductions in the level of government funding in future years;
●	R&D activity and necessary capital of our Medical Segment;
●	reducing operating ~~costs;~~costs and non-essential expenditures;
●	~~expect~~ability to meet ~~our~~ loan agreement covenant ~~requirements in the next twelve months;~~requirements;
●	cash flow requirements;
●	~~funding our business;~~accounts receivable impact and collections;
●	sufficient liquidity to continue business;
●	~~PPP Loan forgiveness;~~
●	~~request maturity extension on PPP Loan;~~

●	~~furlough or layoff eligible employees;~~
●	future results of operations and liquidity;
●	effect of economic disruptions on our business;
●	curtail capital expenditures;
●	government funding for our services;
●	may not have liquidity to repay debt if our lender accelerates payment of our borrowings;
●	manner in which the applicable government will be required to spend funding to remediate various sites;
●	funding operations;
●	fund capital expenditures from cash from operations and/or financing;
●	impact from COVID-19;
●	procurement actions and contract awards;
●	waste receipts and contract awards in the second half of 2021;
●	~~impact from COVID-19;~~
●	returns in waste shipments;
●	fund remediation expenditures for sites from funds generated internally;
●	collection of accounts receivables;
●	compliance with environmental regulations;
●	potential effect of being a PRP;
●	potential sites for violations of environmental laws and remediation of our facilities;
●	continuation of contracts with federal government;
●	~~loss of contracts;~~
●	~~fourth quarter 2020 and first quarter 2021 financial results due to impact of COVID-19;~~
●	partial or full shutdown of any of our facilities;
●	~~liability from Tetra Tech claims;~~
●	~~shutdown of projects and~~ continued waste shipments delays by clients; and
●	~~necessary capital for Medical Segment.~~R&D costs.

While the Company believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors, which could cause future outcomes to differ materially from those described in this report, including, but not limited to:

●	general economic conditions;
●	contract bids, including international markets;
●	material reduction in revenues;
●	inability to meet PNC covenant requirements;
●	inability to collect in a timely manner a material amount of receivables;

●	increased competitive pressures;
●	inability to maintain and obtain required permits and approvals to conduct operations;
●	public not accepting our new technology;
●	inability to develop new and existing technologies in the conduct of operations;
●	inability to maintain and obtain closure and operating insurance requirements;
●	inability to retain or renew certain required permits;
●	discovery of additional contamination or expanded contamination at any of the sites or facilities leased or owned by us or our subsidiaries which would result in a material increase in remediation expenditures;
●	delays at our third-party disposal site can extend collection of our receivables greater than twelve months;
●	refusal of third-party disposal sites to accept our waste;
●	changes in federal, state and local laws and regulations, especially environmental laws and regulations, or in interpretation of such;
●	requirements to obtain permits for TSD activities or licensing requirements to handle low level radioactive materials are limited or lessened;
●	potential increases in equipment, maintenance, operating or labor costs;
●	management retention and development;

●

●	financial valuation of intangible assets is substantially more/less than expected;
●	the requirement to use internally generated funds for purposes not presently anticipated;
●	inability to continue to be profitable on an annualized basis;
●	inability of the Company to maintain the listing of its Common Stock on the NASDAQ;
●	terminations of contracts with government agencies (domestic and foreign) or subcontracts involving government agencies (domestic or foreign), or reduction in amount of waste delivered to the Company under the contracts or subcontracts;
●	renegotiation of contracts involving government agencies (domestic and foreign);
●	federal government’s inability or failure to provide necessary funding to remediate contaminated federal sites;
●	disposal expense accrual could prove to be inadequate in the event the waste requires re-treatment;
●	inability to raise capital on commercially reasonable terms;
●	inability to increase profitable revenue;
●	impact of the COVID-19;
●	~~impact of the COVID-19;~~delays in waste shipments and contract awards;
●	~~audit of our PPP Loan (as discussed below);~~
●	new governmental regulations;
●	lender refuses to waive non-compliance or revise our covenant so that we are in compliance; and
●	risk factors and other factors set forth in “Special Note Regarding Forward-Looking Statements” contained in the Company’s ~~2019~~2020 Form 10-K and the “Forward-Looking Statements” contained in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) of the first quarter 2021 Form 10-Q and this second quarter ~~2020~~2021 Form ~~10-Qs and this third quarter 2020 Form~~ 10-Q.

COVID-19 Impact

~~Since the outbreak~~Our management team continues to proactively update our ongoing business operations and safety plans in an effort to mitigate any potential impact of ~~COVID-19, we have remained~~COVID-19. We continue to remain focused ~~on keeping our employees working and, at the same time, focusing~~ on protecting the health and ~~wellbeing~~well-being of our employees and the communities in which we operate while assuring the continuity of our business ~~operations.~~

~~Our management team has proactively implemented~~operations, particularly in light of emerging new variants of the virus. Similar to most of the U.S., we have relaxed COVID-19 precautions associated with operations since more people have become vaccinated, including our ~~business continuity and safety plans and has taken a variety~~employees. However, our Treatment Segment continues to see unexpected delays in waste shipments from certain customers due to impacts of ~~measures~~COVID-19. We expect to ~~ensure the ongoing availability of our~~see returns in waste treatment and remediation services, while taking health and safety measures, including separating employee and customer contact, social distancing between employees, implementing enhanced cleaning and hygiene protocols in all of our facilities, and implementing remote work policies, when necessary.

~~The COVID-19 pandemic presents potential new risks to our business and results in significant volatility~~receipts from these customers starting in the ~~U.S.~~second half of 2021. Within our Services Segment, we continue to experience delays in procurement actions and ~~international markets.~~contract awards resulting primarily from the impact of COVID-19 but have recently begun to receive new contract awards. Within our Treatment and Services Segments, we have an unprecedented number of bids currently submitted and awaiting awards. We expect procurement actions and contract awards to continue throughout the second half of 2021.

As the situations surrounding COVID-19 continues to remain fluid, the full impact and extent of the pandemic on our financial results and liquidity cannot be estimated with any degree of certainty. We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business. As previously reported, the COVID-19 pandemic did not result in a material impact to the Company’s first quarter 2020 results of operations. Starting in late March 2020, our operations were impacted by the shutdown of a number of projects and the delays of certain waste shipments that continued into the second quarter of 2020. Since the latter part of the second quarter of 2020, all of the projects that were previously shutdown within our Services Segment have restarted as stay-at-home orders and certain other restrictions resulting from the pandemic were lifted. Revenues within our Services Segment in the third quarter of 2020 exceeded the corresponding period of 2019 by approximately $10,652,000. We continue to experience delays in waste shipments from certain customers within our Treatment Segment directly related to the impact of COVID-19business, including generator shutdowns and limited sustained operations, along with other factors. These waste shipment delays may impact our results of operations for the fourth quarter of 2020 and potentially the first quarter of 2021.

At this time, we believe we have sufficient liquidity on hand to continue business operations during the next twelve months. At September 30, 2020, we had cash on hand of approximately $4,811,000 and borrowing availability under our revolving credit facility of approximately $16,404,000 based on a percentage of eligible receivables and subject to certain reserves. In April 2020, we entered into a promissory note (“PPP Loan”) with our credit facility lender in the amount of approximately $5,666,000 under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). On June 5, 2020, the Paycheck Protection Program Flexibility Act of 2020 (the “Flexibility Act”) was signed into law, amending the CARES Act (see “CARES Act – PPP Loan” under “Liquidity and Capital Resources” below for a discussion of the PPP Loan). During the third quarter of 2020, we repaid approximately $348,000 of the PPP Loan resulting from clarification in the loan calculation at the time of the loan origination. On October 5, 2020, we applied for forgiveness on the entire PPP Loan balance as permitted under the program, which is subject to the review and approval of our lender and Small Business Administration (“SBA”). Proceeds from the PPP Loan have allowed us to avoid having to furlough or layoff certain eligible employees as a result of the COVID-19 pandemic, although there are no assurances that such will not be required. We continue to assess reducing operating costs during this volatile time, which include curtailing capital expenditures, eliminating non-essential expenditures and implementing a hiring freeze as needed. We have elected to defer payment of our share of social security taxes as permitted under the CARES Act, as amended (see “CARES Act – Deferral of Employment Tax Deposits” within this MD&A for a discussion of this deferral).

~~We are closely monitoring~~ our customers’ payment performance. However, since a significant portion of our revenues is derived from government related contracts, we do not expect our accounts receivable collections to be materially impacted due to COVID-19.

The situation surrounding COVID-19 continues to remain fluid. The potential for a material impact on our business increases the longer COVID-19 impacts the level of economic activities in the United States and globally as our customers may continue to delay waste shipments and project work may shut down again. ForAt this reason, we cannot reasonably estimate with any degree of certainty the future impact COVID-19 may have on our results of operations, financial position, and liquidity during the next twelve months. As of the date of this report,time, we believe ~~that our cash~~we have sufficient liquidity on hand ~~and our credit facility should provide sufficient liquidity~~ to continue business operations during the next twelve months. At June 30, 2021, our borrowing availability under our revolving credit facility was approximately $9,550,000 which was based on a percentage of eligible receivables and subject to certain reserves. We continue to assess the need in reducing operating costs during this volatile time, which may include curtailing capital expenditures, eliminating non-essential expenditures and implementing a hiring freeze as needed. Based on our current projection, we believe that we will be able to meet ~~the~~our current covenant requirements under our loan agreement for the next twelve months, ~~despite~~however, such may not be the ~~impact~~case due to, among other things, the uncertainty of ~~COVID-19.~~COVID on our operations and/or delays in procurement actions, contract awards, or waste shipments.

Overview

~~Revenue increased $7,637,000~~Our overall revenue decreased $5,902,000 or ~~33.9%~~26.8% to ~~$30,172,000~~$16,145,000 for the three months ended ~~September~~June 30, ~~2020~~2021 from ~~$22,535,000~~$22,047,000 for the corresponding period of ~~2019.~~2020 due primarily from the impact of COVID-19. The ~~increase~~revenue decrease was ~~entirely~~primarily within our Services Segment where revenue ~~increased $10,652,000~~decreased by approximately $5,768,000 or ~~85.5%~~40.6% to $8,439,000 for the three months ended June 30, 2021 from ~~increased projects.~~$14,207,000 for the corresponding period of 2020 primarily due to delays in procurement actions and contract awards resulting primarily from the impact of COVID-19. The completion of a certain large project in the Services Segment in the second quarter exacerbated the decrease in revenue. Revenue within our Treatment Segment decreased $134,000 or 1.7%. Our Treatment Segment’s revenue has been negatively impacted by continued waste shipment delays from certain customers since the latter part of the first quarter of 2020 at the start of the pandemic. However, we expect to see returns in waste receipts from these customers starting in the second half of 2021. Gross profit decreased $2,344,000 or 70.8% primarily due to decreases in revenues in both segments as described above. Selling, General, and Administrative (“SG&A”) expenses increased by approximately 297,000 or 11.0% for the three months ended June 30, 2021 as compared to the corresponding period of 2020.

Our overall revenue decreased $7,629,000 or 16.3% to $39,278,000 for the six months ended June 30, 2021 from $46,907,000 for the corresponding period of 2020. Services Segment revenue decreased by ~~$3,015,000~~$5,427,000 or ~~29.9%~~18.4% to $24,077,000 for the six months ended June 30, 2021 from $29,504,000 for the corresponding period of 2020 primarily due to delays in procurement actions and contract awards as discussed above. Additionally, as discussed above, the completion of a certain large project in the Services Segment in the second quarter of 2021 exacerbated the decrease in revenue. Treatment Segment revenue decreased by $2,202,000 or 12.7% to $15,201,000 for the six months ended June 30, 2021 from $17,403,000 for the corresponding period of 2020 primarily due to continued delays in waste shipments from certain customers ~~resulting from the impact of COVID-19~~ as discussed above. The delays in waste shipments were also partly attributed to the transition of new prime contractors at certain DOE sites. Additionally, lower averaged price waste from revenue mix contributed to the decrease in revenue within the Treatment Segment. GrossTotal gross profit decreased ~~$407,000~~$4,628,000 or ~~7.9% primarily due to the decrease in revenues in the Treatment Segment. Selling, General, and Administrative (“SG&A”) expenses increased by approximately $363,000 or 12.3%~~58.2% for the ~~three~~six months ended ~~September~~June 30, ~~2020~~2021 as compared to the corresponding period of ~~2019.~~

~~Revenue~~2020. Total SG&A expenses increased ~~$25,701,000~~$575,000 or ~~50.0% to $77,079,000~~10.2% for the ~~nine~~six months ended ~~September~~June 30, 2020 from $51,378,000 for the corresponding period of 2019. The increase was entirely within our Services Segment where revenue increased $31,311,000 or 147.0% from increased projects. Our Services Segment experienced this increase in revenue despite a number of our projects being shut down during part of the second quarter 2020. These previously shut down projects have since restarted. Our Treatment Services revenue decreased by $5,610,000 or 18.7% primarily due to continued delays in waste shipments from certain customers resulting from the impact of COVID-19 as discussed above. The delays in waste shipments were also partly attributed to the transition of new prime contractors at certain DOE sites. Total gross profit increased $1,771,000 or 16.2% for the nine months ended September 30, 20202021 as compared to the corresponding period of ~~2019. Total SG&A expenses increased $387,000 or 4.5% for the nine months ended September 30, 2020 as compared to the corresponding period of 2019.~~2020.

Our working capital was ~~$7,020,000~~$3,394,000 at ~~September~~June 30, ~~2020~~2021 as compared to working capital of ~~$26,000~~$3,672,000 at December 31, ~~2019.~~2020. Our working capital was negatively impacted by revenue decreases in both Segments. However, the forgiveness of our Paycheck Protection Program (“PPP”) Loan, along with accrued interest, by the U.S. Small Business Administration (“SBA”) had a positive impact to our working capital (see “The CARES Act – PPP Loan” within this MD&A for a discussion of this loan forgiveness).

Business Environment ~~and Outlook~~

Our Treatment and Services Segments’ business continues to be heavily dependent on services that we provide to governmental clients, primarily as subcontractors for others who are prime contractors to government entities or directly as the ~~contractor or indirectly as a subcontractor.~~prime contractor. We believe demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including, without limitation, the economic conditions, the manner in which the applicable government will be required to spend funding to remediate various sites, and/or the impact resulting from COVID-19 as discussed above. In addition, our governmental contracts and subcontracts relating to activities at governmental sites in the United States are generally subject to termination or renegotiation on 30 days’ notice at the government’s option, and our governmental contracts/task orders with the Canadian government authorities allow the authorities to terminate the contract/task orders at any time for convenience. Significant reductions in the level of governmental funding or specifically mandated levels for different programs that are important to our business could have a material adverse impact on our business, financial position, results of operations and cash flows. As previously disclosed, our Medical Segment continues to evaluate strategic options to commercialize its medical isotope production technology. These options generally require substantial capital to fund R&D requirements, in addition to start-uphas not generated any revenues and ~~production costs. Our Medical Segment~~ has substantially reduced its R&D costs and activities due to the need for capital to fund such activities. We anticipate that our Medical Segment will not resume full R&D activities until it obtains the necessary funding through obtaining its own credit facility or additional equity raise or obtaining new partners willing to fund its R&D activities. If the Medical Segment is unable to raise the necessary capital, the Medical Segment could be required to further reduce, delay or eliminate its R&D program.

We are continually reviewing methods to raise additional capital to supplement our liquidity requirements, when needed, and reducing our operating costs. We continue to aggressively bid on various contracts, including potential contracts within the international markets.

Results of Operations

The reporting of financial results and pertinent discussions are tailored to our three reportable segments: The Treatment, Services, and Medical Segments. Our Medical Segment has not generated any revenue and all costs incurred are included within R&D. ~~Our results of operations for the balance of 2020 could be further subjected to the impact of COVID-19 as discussed above under “COVID-19 Impact.”~~

Summary – Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020

	Three Months Ended												Nine Months Ended												Three Months Ended												Six Months Ended
	September 30,												September 30,												June 30,												June 30,
Consolidated (amounts in thousands)	2020			%			2019			%			2020			%			2019			%			2021			%			2020			%			2021			%			2020			%
Net revenues	$	30,172			100.0		$	22,535			100.0		$	77,079			100.0		$	51,378			100.0		$	16,145			100.0		$	22,047			100.0		$	39,278			100.0		$	46,907			100.0
Cost of goods sold		25,422			84.3			17,378			77.1			64,379			83.5			40,449			78.7			15,179			94.0			18,737			85.0			35,956			91.5			38,957			83.1
Gross profit		4,750			15.7			5,157			22.9			12,700			16.5			10,929			21.3			966			6.0			3,310			15.0			3,322			8.5			7,950			16.9
Selling, general and administrative		3,308			11.0			2,945			13.1			8,935			11.6			8,548			16.6			2,997			18.6			2,700			12.2			6,202			15.8			5,627			12.0
Research and development		157			.4			165			.7			598			.8			615			1.3			144			.9			209			.9			295			.8			441			.9
Loss on disposal of property and equipment		—			—			4			—			27			—			3			—
Income from operations		1,285			4.3			2,043			9.1			3,140			4.1			1,763			3.4
(Gain) loss on disposal of property and equipment																										—			—			(4	)		—			—			—			27			—
(Loss) income from operations																										(2,175	)		(13.5	)		405			1.9			(3,175	)		(8.1	)		1,855			4.0
Interest income		28			.1			77			.3			112			.1			265			.5			2			—			28			.1			21			—			84			.2
Interest expense		(87	)		(.3	)		(99	)		(.4	)		(306	)		(.4	)		(293	)		(.6	)		(65	)		(.4	)		(99	)		(.5	)		(132	)		(.3	)		(219	)		(.5	)
Interest expense-financing fees		(58	)		(.2	)		(69	)		(.3	)		(187	)		(.2	)		(139	)		(.3	)		(9	)		—			(60	)		(.3	)		(17	)		—			(129	)		(.3	)
Other		180			.6			(2	)		—			189			.2			222			.5			—			—			4			—			1			—			9			—
Loss on extinguishment of debt		—			—			—			—			(27	)		—			—			—
Gain (loss) on extinuishment of debt																										5,381			33.3			(27	)		(.1	)		5,381			13.7			(27	)		—
Income from continuing operations before taxes		1,348			4.5			1,950			8.7			2,921			3.8			1,818			3.5			3,134			19.4			251			1.1			2,079			5.3			1,573			3.4
Income tax (benefit) expense		(133	)		(.4	)		55			.3			(128	)		(.2	)		99			.2
Income from continuing operations, net of taxes	$	1,481			4.9		$	1,895			8.4		$	3,049			4.0		$	1,719			3.3
Income tax expense (benefit)																										13			.1			(9	)		(.1	)		(4	)		—			5			—
Income (loss) from continuing operations																									$	3,121			19.3		$	260			1.2		$	2,083			5.3		$	1,568			3.4

Revenues

Consolidated revenues ~~increased $7,637,000~~decreased $5,902,000 for the three months ended ~~September~~June 30, ~~2020,~~2021, compared to the three months ended ~~September~~June 30, ~~2019,~~2020, as follows:

(In thousands)	2020		% Revenue		2019		% Revenue		Change			% Change			2021		% Revenue		2020		% Revenue		Change			% Change
Treatment
Government waste	$	4,950		16.4	$	7,077		31.4	$	(2,127	)		(30.1	)	$	5,102		31.6	$	5,559		25.2	$	(457	)		(8.2	)
Hazardous/non-hazardous ⁽¹⁾		964		3.2		1,309		5.8		(345	)		(26.4	)		1,317		8.1		938		4.3		379			40.4
Other nuclear waste		1,152		3.8		1,695		7.5		(543	)		(32.0	)		1,287		8.0		1,343		6.1		(56	)		(4.2	)
Total		7,066		23.4		10,081		44.7		(3,015	)		(29.9	)		7,706		47.7		7,840		35.6		(134	)		(1.7	)

Services
Nuclear services		22,647		75.1		11,979		53.2		10,668			89.1			8,052		49.9		13,776		62.5		(5,724	)		(41.6	)
Technical services		459		1.5		475		2.1		(16	)		(3.4	)		387		2.4		431		1.9		(44	)		(10.2	)
Total		23,106		76.6		12,454		55.3		10,652			85.5			8,439		52.3		14,207		64.4		(5,768	)		(40.6	)

Total	$	30,172		100.0	$	22,535		100.0	$	7,637			33.9		$	16,145		100.0	$	22,047		100.0	$	(5,902	)		(26.8	)

⁽¹⁾¹⁾Includes wastes generated by government clients of ~~$518,000~~$544,000 and ~~$460,000~~$496,000 for the three month ended ~~September~~June 30, ~~2020~~2021 and the corresponding period of ~~2019,~~2020, respectively.

Treatment Segment revenue decreased ~~$3,015,000~~$134,000 or ~~29.9 %~~1.7% for the three months ended ~~September~~June 30, ~~2020~~2021 over the same period in ~~2019.~~2020. The revenue decrease was attributed primarily to lower revenue from government waste generators resulting from lower waste volume. The increase in hazardous/non hazardous waste was primarily due to higher averaged price waste. Our Treatment Segment revenue ~~was the result of lower~~has been negatively impacted by continued waste ~~volume as~~shipment delays from certain ~~of our~~ customers ~~continue to delay waste shipments~~ since the latter part of the first quarter of 2020 ~~due to~~at the start of the COVID-19 pandemic. Services Segment revenue decreased by approximately $5,768,000 or 40.6%. As previously disclosed, our Services Segment revenue for the second quarter was impacted primarily by delays in procurement actions and contract awards resulting from the impact of COVID-19. The delays in waste shipments were also partly attributed to the transition of new prime contractors at certain DOE sites. Additionally, lower averaged price waste from revenue mix contributed to the decrease in revenue. Services Segment revenue increased by $10,652,000 or 85.5% in the three months ended September 30, 2020 from the corresponding period of 2019. The increase in our Services Segment revenue was primarily due to the increase in number of projects. Our Services Segment revenues are project based; as such, the scope, duration and completion of each project vary. As a result, our Services Segment revenues are subject to differences relating to timing and project value.

Consolidated revenues ~~increased $25,701,000~~decreased $7,629,000 for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, as compared to the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, as follows:

(In thousands)	2020		% Revenue		2019		% Revenue		Change			% Change			2021		% Revenue		2020		% Revenue		Change			% Change
Treatment
Government waste	$	17,576		22.8	$	20,478		39.8	$	(2,902	)		(14.2	)	$	9,489		24.1	$	12,626		26.9	$	(3,137	)		(24.8	)
Hazardous/non-hazardous ⁽¹⁾		3,426		4.4		4,616		9.0		(1,190	)		(25.8	)		2,628		6.7		2,462		5.3		166			6.7
Other nuclear waste		3,467		4.5		4,985		9.7		(1,518	)		(30.5	)		3,084		7.9		2,315		4.9		769			33.2
Total		24,469		31.7		30,079		58.5		(5,610	)		(18.7	)		15,201		38.7		17,403		37.1		(2,202	)		(12.7	)

Services
Nuclear services		51,257		66.5		19,211		37.4		32,046			166.8			23,132		58.9		28,611		61.0		(5,479	)		(19.1	)
Technical services		1,353		1.8		2,088		4.1		(735	)		(35.2	)		945		2.4		893		1.9		52			5.8
Total		52,610		68.3		21,299		41.5		31,311			147.0			24,077		61.3		29,504		62.9		(5,427	)		(18.4	)

Total	$	77,079		100.0	$	51,378		100.0	$	25,701			50.0		$	39,278		100.0	$	46,907		100.0	$	(7,629	)		(16.3	)

⁽¹⁾¹⁾Includes wastes generated by government clients of ~~$1,637,000~~$1,289,000 and ~~$1,728,000~~$1,119,000 for the ~~nine~~six month ended ~~September~~June 30, ~~2020~~2021 and the corresponding period of ~~2019,~~2020, respectively.

Treatment Segment revenue decreased ~~$5,610,000~~$2,202,000 or ~~18.7~~12.7 % for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 over the same period in ~~2019. The revenue decrease was~~2020 primarily due to lower waste volume. As previously disclosed, since the latter part of the first quarter of 2020 at the start of the pandemic, revenue ~~generated from lower waste volume resulting from continued~~within our Treatment Segment has been impacted by waste shipment delays ~~since late March 2020~~ from certain ~~of our~~ customers primarily due to the impact of ~~COVID-19 as discussed above. The delays in~~COVID-19. Within our Treatment Segment, revenue generated from other nuclear waste ~~shipments were also partly attributed~~increased primarily due to ~~the transition of new prime contractors at certain DOE sites. Our~~higher waste volume generated from commercial customers. Services Segment revenue ~~increased $31,311,000~~decreased $5,427,000 or ~~147.0% due to~~18.4% for the ~~increase~~six months ended June 30, 2021 over the same period in ~~number of projects. Our~~2020. As previously disclosed, our Services Segment ~~experienced this increase~~revenue for the first six months of 2021 was impacted by delays in ~~revenue despite a number~~procurement actions and contract awards resulting primarily from the impact of ~~our projects being shut down during part of the second quarter 2020. These previously shut down projects in the Services Segment have since restarted. Additionally,~~COVID-19. Also, our Services Segment revenues are project based; as such, the scope, duration and completion of each project vary. As a result, our Services Segment revenues are subject to differences relating to timing and project value.

Cost of Goods Sold

Cost of goods sold ~~increased $8,044,000~~decreased $3,558,000 for the quarter ended ~~September~~June 30, ~~2020,~~2021, as compared to the quarter ended ~~September~~June 30, ~~2019,~~2020, as follows:

			%				%							%				%
(In thousands)	2020		Revenue		2019		Revenue		Change			2021		Revenue		2020		Revenue		Change
Treatment	$	5,972		84.5	$	6,743		66.9	$	(771	)	$	6,273		81.4	$	6,145		78.4	$	128
Services		19,450		84.2		10,635		85.4		8,815			8,906		105.5		12,592		88.6		(3,686	)
Total	$	25,422		84.3	$	17,378		77.1	$	8,044		$	15,179		94.0	$	18,737		85.0	$	(3,558	)

Cost of goods sold for the Treatment Segment ~~decreased~~increased by approximately ~~$771,000~~$128,000 or ~~11.4% primarily due to the decrease in revenue.~~2.1%. Treatment ~~Segment~~Segment’s variable costs ~~decreased~~increased by approximately ~~$1,207,000~~$136,000 primarily in disposal, transportation, material and supplies and outside ~~services costs due to lower revenues. Our~~services. Treatment Segment’s overall fixed costs were ~~higher~~slightly lower by approximately ~~$436,000~~$8,000 resulting from the following: payroll related expenses were lower by approximately $54,000; maintenance expenses were lower by $54,000; general expenses were higher by ~~$152,000; regulatory expenses were higher by approximately $105,000;~~$52,000 in various categories; depreciation expenses were higher by approximately ~~$134,000 primarily~~$35,000 due to more financed ~~leases that we did not have in the third quarter of 2019; general~~leases; and travel expenses were ~~by $99,000~~ higher ~~in various categories; and salaries and payroll costs were lower~~ by approximately ~~$54,000.~~$13,000 due to ease of travel restrictions since the start of the pandemic. Services Segment cost of goods sold ~~increased $8,815,000~~decreased $3,686,000 or ~~82.9%~~29.3% primarily due to ~~increased revenue as discussed above.~~lower revenue. The ~~increase~~decrease in cost of goods sold was primarily due to ~~higher salaries and~~ lower salaries/payroll ~~costs,~~related, travel, and outside services expenses totaling approximately ~~$7,412,000, higher~~$3,177,000 with the remaining lower costs in material and supplies, disposal, regulatory, and ~~disposal costs totaling approximately $1,243,000, and higher~~ general ~~expenses of $160,000 in various categories. Payroll costs within our Services Segment included higher expenses for project related incentives.~~expenses. Included within cost of goods sold is depreciation and amortization expense of ~~$469,000~~$394,000 and ~~$317,000~~$358,000 for the three months ended ~~September~~June 30, 2021, and 2020, ~~and 2019,~~ respectively.

Cost of goods sold ~~increased $23,930,000~~decreased $3,001,000 for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, as compared to the ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, as follows:

			%				%							%				%
(In thousands)	2020		Revenue		2019		Revenue		Change			2021		Revenue		2020		Revenue		Change
Treatment	$	18,936		77.4	$	21,158		70.3	$	(2,222	)	$	12,843		84.5	$	12,963		74.5	$	(120	)
Services		45,443		86.4		19,291		90.6		26,152			23,113		96.0		25,994		88.1		(2,881	)
Total	$	64,379		83.5	$	40,449		78.7	$	23,930		$	35,956		91.5	$	38,957		83.1	$	(3,001	)

Cost of goods sold for the Treatment Segment decreased by approximately ~~$2,222,000~~$120,000 or ~~10.5%~~0.9%. Treatment Segment costs of goods sold for the nine months ended September 30, 2019 included additional closure costs recorded in the amount of $330,000 for our East Tennessee Materials and Energy Corporation (“M&EC”) facility due to finalization of closure requirements in connection with the closure of the facility. Excluding the closure costs recorded in the nine months of 2019, Treatment Segment cost of goods sold decreased $1,892,000 or 9.1% primarily due to the decrease in revenue. Excluding the closure costs recorded in the nine months ended September 30, 2019, Treatment SegmentSegment’s variable costs decreased by approximately ~~$2,491,000~~$289,000 primarily ~~due to lower~~in disposal, transportation, material and supplies and outside services ~~costs. Our~~due to lower revenue. Treatment Segment’s overall fixed costs were higher by approximately ~~$599,000~~$169,000 resulting from the following: ~~maintenance~~general expenses were higher by ~~$380,000;~~$171,000 in various categories; depreciation expenses were higher by approximately $80,000 due to more financed leases; regulatory expenses were higher by approximately ~~$155,000; depreciation expenses were higher by approximately $212,000 primarily due to more financed leases; general~~$23,000; maintenance expenses were lower by ~~approximately $131,000 higher in various categories;~~$89,000; and ~~salaries and payroll costs~~travel expenses were lower by ~~approximately $17,000.~~$16,000 due to restrictions implemented from the impact of COVID-19. Services Segment cost of goods sold ~~increased $26,152,000~~decreased $2,881,000 or ~~135.6%~~11.1% primarily due to ~~the increase in~~lower revenue. The ~~increase~~decrease in cost of goods sold ~~within our Services Segment~~ was primarily due to ~~higher salaries and~~ lower salaries/payroll ~~costs,~~related, travel, and outside services expenses totaling approximately ~~$22,810,000, higher~~$2,082,000 with the remaining lower costs in material and supplies, disposal, regulatory, and ~~disposal costs totaling approximately $2,688,000, and higher~~ general ~~expenses of $654,000 in various categories. Payroll costs within our Services Segment included higher expenses for project related incentives.~~expenses. Included within cost of goods sold is depreciation and amortization expense of ~~$1,169,000~~$787,000 and ~~$934,000~~$699,000 for the ~~nine~~six months ended ~~September~~June 30, 2021, and 2020, ~~and 2019,~~ respectively.

Gross Profit (Negative Gross Profit)

Gross profit for the quarter ended ~~September~~June 30, ~~2020~~2021 decreased ~~$407,000~~$2,344,000 over the same period ~~of 2019,~~in 2020, as follows:

			%				%								%					%
(In thousands)	2020		Revenue		2019		Revenue		Change			2021			Revenue			2020		Revenue		Change
Treatment	$	1,094		15.5	$	3,338		33.1	$	(2,244	)	$	1,433			18.6		$	1,695		21.6	$	(262	)
Services		3,656		15.8		1,819		14.6		1,837			(467	)		(5.5	)		1,615		11.4		(2,082	)
Total	$	4,750		15.7	$	5,157		22.9	$	(407	)	$	966			6.0		$	3,310		15.0	$	(2,344	)

Treatment Segment gross profit decreased by ~~$2,244,000 or 67.2%~~$262,000 and gross margin decreased to ~~15.5%~~18.6% from ~~33.1%~~21.6% primarily due to lower revenue from lower waste volume and ~~lower averaged price waste from revenue mix. The increases in gross profit in~~ the ~~Services Segment~~impact of ~~$1,837,000 or 101.0% and gross margin from 14.6% to 15.8% was primarily due to the increase in revenue as discussed above. Additionally,~~ our ~~overall~~fixed costs. Services ~~Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.~~

~~Gross profit for the nine months ended September 30, 2020 increased $1,771,000 over the same period in 2019, as follows:~~

% %
(In thousands) 2020 Revenue 2019 Revenue Change
Treatment $ 5,533 22.6 $ 8,921 29.7 $ (3,388 )
Services 7,167 13.6 2,008 9.4 5,159
Total $ 12,700 16.5 $ 10,929 21.3 $ 1,771

~~Treatment~~ Segment gross profit decreased ~~$3,388,000~~by $2,082,000 or ~~38.0%~~128.9% and gross margin decreased from 11.4% to 22.6% from 29.7%. Excluding the additional closure costs of $330,000 recorded in the nine months ended September 30, 2019 in connection with the closure of our M&EC facility as discussed previously, gross profit decreased $3,718,000 or 40.2% and gross margin decreased to 22.6% from 30.8% primarily due lower revenue from lower waste volume. In the Services Segment, gross profit increased $5,159,000 or 256.9% and gross margin increased from 9.4% to 13.6%a negative 5.5% primarily due to ~~the increase in~~lower revenue. Our overall Services Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.

Gross profit for the six months ended June 30, 2021 decreased $4,628,000 over 2020, as follows:

			%				%
(In thousands)	2021		Revenue		2020		Revenue		Change
Treatment	$	2,358		15.5	$	4,440		25.5	$	(2,082	)
Services		964		4.0		3,510		11.9		(2,546	)
Total	$	3,322		8.5	$	7,950		16.9	$	(4,628	)

Treatment Segment gross profit decreased by $2,082,000 and gross margin decreased to 15.5% from 25.5% primarily due to lower revenue from lower waste volume and the impact of our fixed costs. Services Segment gross profit decreased by $2,546,000 or 72.5% and gross margin decreased from 11.9% to 4.0% primarily due to lower revenue. Our overall Services Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.

SG&A

SG&A expenses increased ~~$363,000~~$297,000 for the three months ended ~~September~~June 30, ~~2020,~~2021, as compared to the corresponding period for ~~2019,~~2020, as follows:

(In thousands)	2020		% Revenue		2019		% Revenue		Change			2021		% Revenue		2020		% Revenue		Change
Administrative	$	1,564		—	$	1,340		—	$	224		$	1,291		—	$	1,296		—	$	(5	)
Treatment		910		12.9		988		9.8		(78	)		901		11.7		867		11.1		34
Services		834		3.6		617		5.0		217			805		9.5		537		3.8		268
Total	$	3,308		11.0	$	2,945		13.1	$	363		$	2,997		18.6	$	2,700		12.2	$	297

~~Our Administrative~~The overall increase in SG&A was ~~higher~~ primarily ~~due to the following: general~~within our Services Segment where SG&A expenses ~~were higher~~increased by approximately ~~$34,000~~$268,000. The increase in various categories; director stock option expenses were higher by approximately $25,000 due to options granted to new directors in addition to higher fair value of options granted to re-elected directors; salaries and payroll expenses were higher by approximately $121,000 which included higher estimated progress expenses related to the Company’s incentive plans; outside services expense was higher by approximately $69,000 resulting from more consulting/subcontract matters; and travel expense was lower by approximately $25,000 due to restrictions implemented resulting from the impact of COVID-19. Our Treatment Segment SG&A ~~was lower primarily due to the following: travel expense were lower by approximately $36,000 due to restrictions implemented resulting from the impact of COVID-19; general~~ expenses ~~were lower by $22,000 in various categories; and bad debt expenses were lower by approximately $20,000. The higher SG&A costs~~ within our Services Segment was primarily due to the following: salaries and payroll related expenses were higher by approximately ~~$268,000; general~~$185,000 primarily due to increased hours spent for bid and proposals and higher healthcare costs; travel expenses were higher by approximately ~~$25,000 in various categories;~~$12,000 due to ease of travel restrictions since the start of the pandemic; outside services expenses were higher by ~~$23,000; travel expense was lower by~~ approximately ~~$24,000~~$92,000 primarily due to ~~restrictions implemented resulting from the impact of COVID-19;~~more consulting matters related to bid and ~~bad debt~~proposals; and general expenses were lower by approximately ~~$75,000.~~$21,000. Administrative SG&A expenses were slightly lower primarily due to the following: payroll related expenses were lower by approximately $98,000 primarily due to forfeiture of 401(k) plan matching funds contributed by us for former employees who failed to meet the 401(k) plan vesting requirements; director fees were higher by approximately $60,000 resulting from one additional director and fee increases that went into effect January 1, 2021; travel expenses were higher by approximately $13,000 due to ease of travel restrictions since the pandemic; outside services expenses were higher by approximately $14,000 resulting from more consulting/subcontract/legal matters; and general expenses were slightly higher by approximately $6,000. Treatment Segment SG&A expenses were higher due to the following: bad debt expenses were higher by approximately $69,000 as in the second quarter of 2020, certain customer accounts which had previously been reserved for were collected; travel expenses were slightly higher by approximately $5,000 due to ease of travel restrictions since the start of the pandemic; general expenses were slightly higher by approximately $10,000; and salaries and payroll related expenses were lower by approximately $50,000. Included in SG&A expenses is depreciation and amortization expense of ~~$9,000~~$6,000 and ~~$11,000~~$6,000 for the three months ended ~~September~~June 30, 2021, and 2020, ~~and 2019,~~ respectively.

SG&A expenses increased ~~$387,000~~$575,000 for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, as compared to the corresponding period for ~~2019,~~2020, as follows:

(In thousands)	2020		% Revenue		2019		% Revenue		Change			2021		% Revenue		2020		% Revenue		Change
Administrative	$	4,219		—	$	3,905		—	$	314		$	2,662		—	$	2,655		—	$	7
Treatment		2,838		11.6		2,966		9.9		(128	)		1,880		12.4		1,928		11.1		(48	)
Services		1,878		3.6		1,677		7.9		201			1,660		6.9		1,044		3.5		616
Total	$	8,935		11.6	$	8,548		16.6	$	387		$	6,202		15.8	$	5,627		12.0	$	575

The overall increase in SG&A was primarily within our Services Segment where SG&A expenses increased by approximately $616,000. The increase in ~~Administrative~~ SG&A expenses within our Services Segment was primarily due to the following: ~~general~~salaries and payroll related expenses were higher by approximately ~~$73,000 in various categories; director stock option~~$371,000 primarily due to increased hours spent for bid and proposals; outside services expenses were higher by approximately ~~$47,000~~$192,000 due to ~~options granted~~more consulting matters related to ~~new directors in addition to higher fair value of options granted to re-elected directors; salaries~~bid and ~~payroll~~proposals; bad debt expenses were higher by approximately ~~$161,000~~$40,000 as in the first quarter of 2020, certain customer accounts which ~~included~~had previously been reserved for were collected; and general expenses were slightly higher ~~estimated progress~~by $13,000. Administrative SG&A expenses ~~related~~were slightly higher primarily due to the ~~Company’s incentive plans; outside services expense was~~following: director fees were higher by approximately ~~$73,000~~$119,000 resulting from ~~more consulting/subcontract matters;~~one additional director and ~~travel expense was~~fee increases that went into effect January 1, 2021; general expenses were slightly higher by approximately $5,000; payroll related expenses were lower by approximately ~~$40,000~~$79,000 primarily due to ~~restrictions implemented~~forfeiture of 401(k) plan matching funds contributed by us for former employees which failed to meet the 401(k) plan vesting requirements; travel expenses were lower by approximately $10,000 due to less travel due to COVID-19; and outside services expenses were lower by approximately $28,000 resulting from ~~the impact of COVID-19.~~fewer consulting/subcontract/legal matters. Treatment Segment SG&A ~~was~~expenses were lower ~~primarily~~ due to the following: travel expenses were lower by approximately ~~$61,000~~$44,000 due to ~~restrictions implemented~~less travel resulting from ~~the impact of~~ COVID-19; general expenses were lower by ~~$11,000~~$101,000 in various categories; bad debt expenses were ~~lower~~higher by approximately ~~$76,000; outside services costs~~$50,000 as in the second quarter of 2020, certain customer accounts which had previously been reserved for were ~~slightly higher by $6,000 and~~collected; salaries and payroll related expenses were higher by approximately ~~$14,000. Services Segment SG&A increased by $201,000 primarily~~$36,000 due to ~~the following: general expenses were~~increased hours spent on bid and proposals and higher ~~by approximately $48,000 in various categories; salaries~~healthcare costs; and ~~payroll expenses were higher by approximately $393,000;~~ outside services expenses were higher by approximately ~~$13,000; travel expenses were lower by approximately $88,000~~$11,000 primarily due to restrictions implemented resulting from the impact of COVID-19; and bad debt expenses were lower by approximately $165,000 as certain customer accounts which we had previously reserved for were collected in the first nine months ~~of 2020.~~more consulting matters. Included in SG&A expenses is depreciation and amortization expense of ~~$20,000~~$12,000 and ~~$34,000~~$12,000 for the ~~nine~~six months ended ~~September~~June 30, 2021 and 2020, ~~and 2019,~~ respectively.

R&D

R&D expenses decreased ~~$8,000~~$65,000 and ~~$17,000~~$146,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, as compared to the corresponding period of ~~2019.~~2020.

	Three Months Ended June 30,							Six Months Ended June 30,
(In thousands)	2021		2020		Change			2021		2020		Change
Administrative	$	10	$	37	$	(27	)	$	24	$	44	$	(20	)
Treatment		43		52		(9	)		90		145		(55	)
Services		19		46		(27	)		32		112		(80	)
PF Medical		72		74		(2	)		149		140		9
Total	$	144	$	209	$	(65	)	$	295	$	441	$	(146	)

Three Months Ended September 30, Nine Months Ended September 30,
(In thousands) 2020 2019 Change 2020 2019 Change
Administrative $ 20 $ 6 $ 14 $ 64 $ 20 $ 44
Treatment 49 85 (36 ) 194 367 (173 )
Services 7 — 7 119 — 119
PF Medical 81 74 7 221 228 (7 )
Total $ 157 $ 165 $ (8 ) $ 598 $ 615 $ (17 )

R&D costs consist primarily of employee salaries and benefits, laboratory costs, third party fees, and other related costs associated with the development of new technologies and technological enhancement of new potential waste treatment processes.

Interest Income

Interest income decreased by approximately ~~$49,000~~$26,000 and ~~$153,000~~$63,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, as compared to the corresponding period of ~~2019. The decrease was~~2020 primarily due ~~to lower interest earned on the finite risk sinking funds from lower interest rate. The decrease in interest income was also attributed~~ to lower interest earned from lower finite risk sinking fund balance resulting from the release of $5,000,000 in finite risk sinking funds by AIG Specialty Insurance Company (“AIG”) to us at the end of July 2019 in connection with the closure of our M&EC facility. The $5,000,000 in finite sinking funds represented a partial release of the total collateral held under our finite risk insurance policy.fund.

Interest Expense

Interest expense decreased by approximately ~~$12,000~~$34,000 and ~~increased by $13,000~~$87,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, as compared to the corresponding period of ~~2019. The decrease in interest expense for the three months ended September 30,~~ 2020 ~~was~~ primarily due to lower interest expense from our declining term loan balance outstanding and lower interest rate. Also, interest expense was lower resulting from ~~declining loan balance outstanding on~~the payoff of the $2,500,000 loan at year end 2020 that we had previously entered into with Robert Ferguson on April 1, 2019. The overall decrease in interest expense was partially offset by higher interest expense from more finance leases and interest accrued for the PPP Loan. The increase in interest expense for the nine months ended September 30, 2020 as compared to the corresponding period was primarily due to higher interest expense from more finance leases and interest accrued for the PPP Loan. The higher interest expense was offset by lower interest from our declining loan balances on the term loan and the Ferguson loan as discussed above.

Interest Expense- Financing Fees

Interest expense-financing fees decreased by approximately ~~$11,000~~$51,000 and ~~increased $48,000~~$112,000 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, as compared to the corresponding period ~~of 2019. The decrease in interest expense-financing fees in the third quarter of~~ 2020 was primarily due to lower amortization of debt issuance costs in connection with our new credit facility dated May 8, 2020 as compared to our previous credit facility. On May 8, 2020, we entered into a new credit facility with our lender which resulted in a loss on debt extinguishment of approximately $27,000. The increase in interest expense-financing fees of approximately $48,000 for the nine months ended September 30, 2020 was primarily due to debt discount/debt issuance costs that became fully amortized as financing fees at year end 2020 in connection with the issuance of our Common Stock and a purchase Warrant as consideration for ~~the Company~~us receiving the $2,500,000 loan from Robert Ferguson ondated April 1, ~~2019 (See “Liquidity and Capital Resources – Financing Activities” for further information of this debt discount and the new credit facility dated May 8, 2020).~~2019.

~~Income Taxes~~

We had an income tax benefit of $133,000 and income tax expense of $55,000 for continuing operations for the three months ended September 30, 2020 and 2019, respectively and an income tax benefit of $128,000 and income tax expense of $99,000 for the nine months ended September 30, 2020 and 2019, respectively. Our effective tax rates were approximately 9.9% and 2.8% for the three months ended September 30, 2020 and 2019, respectively, and 4.4% and 5.4% for the nine months ended September 30, 2020 and 2019, respectively. The tax benefit and expense for the periods above were comprised of state tax benefit and expense for separate company filing states. Our tax rate for each of the periods discussed above was impacted by our full valuation on our net deferred tax assets. The income tax benefit for the three and nine months ended September 30, 2020 included refunds from amended state returns filed in separate company filing states.

~~Discontinued Operations and Divestitures~~

~~Our discontinued operations consist of all our subsidiaries included in our Industrial Segment which encompasses subsidiaries divested in 2011 and prior and three previously closed locations.~~

Our discontinued operations had no revenue for the three and nine months ended September 30, 2020 and the corresponding period of 2019. We incurred net losses of $67,000 and $266,000 for our discontinued operations for the three and nine months ended September 30, 2020, respectively. We incurred net losses of $156,000 and $424,000 for our discontinued operations for the three and nine months ended September 30, 2019, respectively.

Liquidity and Capital Resources

Our cash flow requirements during the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily financed by our operations, cash on hand and credit facility ~~availability, and the PPP Loan that we received under the CARES Act as discussed below (see “CARES Act – PPP Loan”). We generated approximately $3,503,000 cash from our continuing operations.~~availability. Subject to the impact of COVID-19 as discussed above, our cash flow requirements for the next twelve months will consist primarily of general working capital needs, scheduled principal payments on our debt obligations, remediation projects, and planned capital expenditures. We plan to fund these requirements from our operations, credit facility availability, ~~and~~our capital expenditure line, cash on hand ~~which was approximately $4,811,000 at September 30, 2020. We continue~~and, if deemed appropriate, other sources available to ~~explore all sources of increasing our capital to supplement our liquidity requirements, when needed, and to improve our revenue and working capital.~~us. We are continually reviewing operating costs and reviewing the possibility of further reducing operating costs and non-essential expenditures to bring them in line with revenue levels, when necessary. At this time, we believe that our cash flows from operations, our available liquidity from our credit facility, our capital expenditure line and our cash on hand should be sufficient to fund our operations for the next twelve months. However, due to the uncertainty of COVID-19, continued delays in waste shipments from certain customers, delays in procurement actions and contract awards, and/or certain reserves that our lender has placed (see the amendment that we entered into with our lender in August 2021 in “Financing Activities” below) or may place in the future against our revolving line of credit, there are no assurances such will be the ~~case in the events that certain of our customers~~case. As a result, we continue to ~~delay waste shipments and/~~explore all sources, including, but not limited to, selling additional stock of ours under our currently effective shelf registration, to increase our capital or ~~elect to shut down projects again due to continue surge in outbreak of COVID-19.~~ supplement our liquidity requirements and working capital. As previously disclosed, our Medical Segment, which has not generated any revenues, has substantially reduced its R&D costs and activities due to the need for capital to fund such activities. We continue to seek various sources of potential funding for our Medical Segment. We anticipate that our Medical Segment will not resume full R&D activities until it obtains the necessary funding through obtaining its own credit facility or additional equity raise or obtaining new partners willing to fund its R&D activities. If the Medical Segment is unable to raise the necessary capital, the Medical Segment could be required to further reduce, delay or eliminate its R&D program.

We are aware that PPP loans in excess of $2,000,000 may be subject to being audited by the appropriate governmental authority. If our PPP Loan is audited, it is currently unknown how our PPP Loan could be affected by an audit. An audit could result, among other things, in us being required to return all or a portion of our PPP Loan (see discussion below as to the PPP Loan under “The CARES Act – PPP Loan”).

The following table reflects the cash flow activities during the first ~~nine~~six months of ~~2020:~~2021:

(In thousands)
Cash provided by operating activities of continuing operations	$	3,503		$	803
Cash used in operating activities of discontinued operations		(329	)		(315	)
Cash used in investing activities of continuing operations		(1,484	)		(649	)
Cash provided by investing activities of discontinued operations		118
Cash provided by financing activities of continuing operations		2,728
Cash used in financing activities of continuing operations					(439	)
Effect of exchange rate changes in cash		(4	)		9
Increase in cash and finite risk sinking fund (restricted cash)	$	4,532
Decrease in cash and finite risk sinking fund (restricted cash)				$	(591	)

At ~~September~~June 30, ~~2020,~~2021, we were in a positive cash position with no revolving credit balance. At ~~September~~June 30, ~~2020,~~2021, we had cash on hand of approximately ~~$4,811,000,~~$7,312,000, which includes account balances of our foreign subsidiaries totaling approximately ~~$157,000.~~$675,000.

Operating Activities

Accounts receivable, net of allowances for doubtful accounts, totaled ~~$13,442,000~~$9,244,000 at ~~September~~June 30, ~~2020, an increase~~2021, a decrease of ~~$264,000~~$415,000 from the December 31, ~~2019~~2020 balance of ~~$13,178,000.~~$9,659,000. The ~~increase~~decrease was primarily due to timing of ~~invoicing which was reflective of the increase in our unbilled receivables~~accounts receivable collection and timing of invoicing. Our contracts with our ~~accounts receivable collection. We provide a variety of~~customers are subject to various payment terms ~~to our customers;~~and conditions; therefore, our accounts receivable are impacted by these terms and conditions and the related timing of accounts receivable collections. ~~The amount~~Additionally, contracts with our customers may sometimes result in modifications which can cause delays in collections.

Unbilled receivables totaled $7,332,000 at June 30, 2021, a decrease of ~~our accounts receivables and collection could be materially impacted the longer COVID-19 persists.~~

~~Accounts payable, totaled $14,652,000 at September 30, 2020, an increase of $5,375,000~~$7,121,000 from the December 31, ~~2019~~2020 balance of ~~$9,277,000.~~$14,453,000. The ~~increase~~decrease in ~~accounts payable~~unbilled receivables was ~~attributed to an increase in costs~~primarily within our Services Segment ~~resulting~~due to invoicing and collection of accounts receivable on certain large projects which have been completed or are near completion.

Accounts payable, totaled $11,511,000 at June 30, 2021, a decrease of $3,871,000 from the ~~significant increase in revenue. Additionally, our~~December 31, 2020 balance of $15,382,000. Our accounts payable are impacted by the timing of payments as we are continually managing payment terms with our vendors to maximize our cash position throughout all segments.

We had working capital of ~~$7,020,000~~$3,394,000 (which included working capital of our discontinued operations) at ~~September~~June 30, ~~2020,~~2021, as compared to working capital of ~~$26,000~~$3,672,000 at December 31, ~~2019. The improvement~~2020. Our working capital was primarily negatively impacted by lower revenue generated within both of our segments in the first six months of 2021. However, this negative impact to our working capital was ~~primarily due to~~positively impacted by the ~~proceeds that we received from~~forgiveness of the entire balance of our PPP Loan, under the Paycheck Protection Program (see “PPP Loan” under “CARES Act” below for a discussion of this loan) and the increase in our unbilled receivables from the significant increase in revenues within the Services Segment. The improvement in our working capital was partially offsetalong with accrued interest, by the ~~increase in our accounts payable.~~SBA effective June 15, 2021 (see “CARES Act – PPP Loan” for information on this loan”).

Investing Activities

For the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, our purchases of capital equipment totaled approximately ~~$2,371,000,~~$679,000, of which ~~$883,000~~$29,000 was subject to financing, with the remaining funded from cash from operations and our credit facility. We have budgeted approximately $2,000,000 for ~~2020~~2021 capital expenditures ~~(net of financed amounts)~~primarily for our Treatment and Services Segments to maintain operations and regulatory compliance requirements and support revenue growth. Certain of these budgeted projects may either be delayed until later years or deferred altogether. We plan to fund our capital expenditures from cash from operations and/or financing. The initiation and timing of projects are also determined by financing alternatives or funds available for such capital ~~projects, especially in light of the uncertainties that COVID-19 may impact the economy which may have an adverse impact to our results of operations and liquidity.~~projects.

Financing Activities

We entered into ana Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated ~~October 31, 2011~~May 8, 2020 (“~~Amended~~ Loan Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The ~~Amended~~ Loan Agreement ~~had been amended from time to time since the execution of the Amended Loan Agreement. The Amended Loan Agreement, as subsequently amended (“Revised Loan Agreement”), provided~~provides us with the following credit facility with a maturity date of March ~~24, 2021:~~15, 2024: (a) up to ~~$12,000,000~~$18,000,000 revolving credit (“revolving credit”) and (b) a term loan (“term loan”) of approximately ~~$6,100,000.~~$1,742,000, requiring monthly installments of $35,547. The maximum that we can borrow under the revolving credit ~~was~~is based on a percentage of eligible receivables (as defined) at any one time reduced by outstanding standby letters of credit and borrowing reductions that our lender may impose from time to time.

~~Payment~~On May 4, 2021, we entered into an amendment to our Loan Agreement with our lender which provided the following, among other things:

	●	revised our fixed charge coverage ratio (“FCCR”) calculation requirement which allows for the add-back of approximately $5,318,000 in eligible expenses that were incurred and covered by the PPP Loan that we received in 2020. The add-back is to be applied retroactively to the second and third quarters of 2020. (see below for a discussion of the PPP Loan); and
	●	a capital expenditure line of up to $1,000,000 with advances on the line, subject to certain limitations, permitted for up to twelve months starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during the Borrowing Period (see annual rate of interest below on the capital expenditure line). At the end of the Borrowing Period, the total amount advanced under the line will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of June 30, 2021.

In connection with the amendment, we paid our lender a fee of $15,000.

Pursuant to our Loan Agreement, as amended, payment of annual rate of interest due on the revolving credit ~~under the Revised Loan Agreement was~~is at prime (3.25% at ~~September~~June 30, ~~2020)~~2021) plus 2% ~~and the term loan at prime plus 2.5%.~~

On May 8, 2020, we entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement (the “New Loan Agreement”) with PNC, replacing our previous Revised Loan Agreement with PNC. The New Loan Agreement provides us with the following credit facility:

	●	~~up to $18,000,000 revolving credit facility, subject to the amount of borrowings based on a percentage of eligible receivables and subject to certain reserves; and~~

	●	~~a term loan of $1,741,818, which requires monthly installments of $35,547.~~

~~The New Loan Agreement terminates as of May 15, 2024, unless sooner terminated.~~

Similar to our Revised Loan Agreement, the New Loan Agreement requires us to meet certain customary financial covenants, including, among other things, a minimum Tangible Adjusted Net Worth requirement of $27,000,000 at all times; maximum capital spending of $6,000,000 annually; and a minimum fixed charge coverage ratio (“FCCR”) requirement of 1.15:1.

~~Under the New Loan Agreement, payment of annual rate of interest due on the credit facility is as follows:~~

●	~~revolving credit at prime plus 2.50%~~ or London InterBank Offer Rate (“LIBOR”) ~~plus 3.50% and the term loan at prime plus 3.00% or LIBOR plus 4.00%. We can only elect to use the LIBOR interest payment option after we become compliant with meeting the minimum FCCR of 1.15:1; and~~

●	~~Upon the achievement of a FCCR of greater than 1.25:1, we have the option of paying an annual rate of interest due on the revolving credit at prime plus 2.00% or LIBOR~~ plus 3.00% and the term loan and capital expenditure line at prime plus 2.50% or LIBOR plus 3.50%. We met this FCCR in the first, second and third quarters of 2020. Upon meeting the FCCR of 1.25:1, this interest payment option will remain in place in the event that our future FCCR falls below 1.25:1.

Under the LIBOR option of interest payment, ~~noted above,~~ a LIBOR floor of 0.75% ~~shall apply~~applies in the event that LIBOR falls below 0.75% at any point in time.

~~Pursuant~~On August 10, 2021, we entered into an amendment to ~~the New~~our Loan Agreement with our lender which provided, among other things, the following:

	●	waived our failure to meet the minimum quarterly FCCR requirement for the second quarter of 2021;
	●	removes the quarterly FCCR testing requirement for the third quarter of 2021;
	●	reinstates the quarterly FCCR testing requirement starting for the fourth quarter of 2021 and revises the methodology to be used in calculating the FCCR for the quarters ending December 31, 2021, March 31, 2022, and June 30, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter); and
	●	requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended December 31, 2021 has been met and certified to the lender.

In connection with the amendment, we paid our lender a fee of $15,000.

We may terminate ~~the New~~our Loan Agreement upon 90 days’ prior written notice upon payment in full of our obligations under the ~~New~~ Loan Agreement. We ~~have~~ agreed to pay PNC 1.0% of the total financing ~~in the event~~had we ~~pay~~paid off our obligations on or before May 7, 2021 and 0.5% of the total financing if we ~~pays~~pay off our obligations after May 7, 2021 but prior to or on May 7, 2022. No early termination fee ~~shall~~will apply if we pay off our obligations under the ~~New~~ Loan Agreement after May 7, 2022.

At ~~September~~June 30, ~~2020,~~2021, the borrowing availability under our revolving credit was approximately ~~$16,404,000,~~$9,550,000, based on our eligible receivables and includes a reduction in borrowing availability of approximately ~~$3,026,000~~$3,020,000 from outstanding standby letters of credit.

Our credit facility under our ~~Revised and New~~ Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. We met our ~~FCCR requirement in the first, second and third quarters of 2020. Additionally, we met our remaining~~ financial covenant requirements in the first quarter of 2021. Our FCCR calculation in the first quarter of 2021 included the add-back of approximately $5,318,000 in eligible expenses that were incurred and covered by the PPP Loan that we received in 2020 as permitted by the amendment dated May 4, 2021 as discussed above. We did not meet our FCCR requirement in the second ~~and third quarters~~quarter of ~~2020.~~2021; however, this non-compliance was waived by our lender as discussed above. We expect to meet our quarterly financial covenant requirements infor the next twelve months; however, if we fail to meet any of our financial covenant requirements and our lender does not further waive the non-compliance or revise our covenant so that we are in compliance, our lender could accelerate the repayment of borrowingsmonths under our ~~credit facility. In the event that our lender accelerates the payment of our borrowings, we may not have sufficient liquidity to repay our debt under our credit facility and other indebtedness.~~

As previously disclosed, on April 1, 2019, we completed a lending transaction with Robert Ferguson (the “Lender”), whereby we borrowed from the Lender the sum of $2,500,000 pursuant to the terms of a Loan ~~and Security Purchase~~ Agreement, and promissory note (the “Loan”). The Lender is a shareholder of ours and also serves as a consultant to us in connection with our Test Bed Initiative (“TBI”) at our Perma-Fix Northwest Richland, Inc. (“PFNWR”) subsidiary. The proceeds from the Loan were used for general working capital purposes. The Loan is unsecured, with a term of two years with interest payable at a fixed interest rate of 4.00% per annum. The Loan provides for monthly payments of accrued interest only during the first year of the Loan, with the first interest payment due May 1, 2019 and monthly payments of approximately $208,333 in principal plus accrued interest starting in the second year of the Loan. The Loan also allows for prepayment of principal payments over the term of the Loan without penalty with such prepayment of principal payments to be applied to the second year of the loan payments at our discretion. Since inception of the loan, we have made total prepayments in principal of $936,000, of which $416,000 was made in the first nine months of 2020. In connection with this capital raise transaction described above and consideration for us receiving the Loan, we issued a Warrant (the “Warrant”) to the Lender to purchase up to 60,000 shares of our Common Stock at an exercise price of $3.51 per share, which was the closing bid price for a share of our Common Stock on NASDAQ.com immediately preceding the execution of the Loan and Warrant. The Warrant expires on April 1, 2024 and remains outstanding at September 30, 2020. As further consideration for this capital raise transaction relating to the Loan, we also issued 75,000 shares of its Common Stock to the Lender. The fair value of the Warrant and Common Stock and the related closing fees incurred from the transaction totaled approximately $398,000 and was recorded as debt discount/debt issuance costs, which is being amortized over the term of the loan as interest expense – financing fees. The 75,000 shares of Common Stock, the Warrant and the 60,000 shares of Common Stock that may be purchased under the Warrant were and will be issued in a private placement that was and will be exempt from registration under Rule 506 and/or Sections 4(a)(2) and 4(a)(5) of the Securities Act of 1933, as amended, ~~(the “Act”) and bear a restrictive legend against resale except in a transaction registered under the Act or in a transaction exempt from registration thereunder.~~as discussed above.

The CARES Act

PPP Loan

On April 14, 2020, we entered into a promissory note under the PPP with PNC, our credit facility lender, ~~in the amount~~which had a balance of approximately ~~$5,666,000 under the PPP~~$5,318,000 (the “PPP Loan”). at March 31, 2021. The PPP was established under the Coronavirus Aid, Relief, and Economic Security Act (“CARES ~~Act~~Act”) and is administered by the SBA. ~~On June 5, 2020,~~The CARES Act was subsequently amended by the Paycheck Protection Program Flexibility Act of 2020 (“Flexibility Act”) was signed into law which amended the CARES Act. The note evidencing the PPP Loan contains events of default relating to, among other things, payment defaults, breach of representations and warranties, and provisions of. Proceeds from the promissory ~~note. During the third quarter of 2020, we repaid approximately $348,000 of the PPP Loan to PNC resulting from clarification in the loan calculation at the time of the loan origination.~~

Under the terms of the Flexibility Act, we can apply for and be granted forgiveness for all or a portion of the PPP Loan. Such forgiveness will be determined, subject to limitations, based on the use of loan proceedsnote was used by us for eligible payroll costs, mortgage interest, rent and utility costs ~~and~~as permitted under the ~~maintenance of employee and compensation levels for the covered period (which is defined as a 24 week period, beginning April 14, 2020, the date in which proceeds from~~Flexibility Act. The annual interest rate on the PPP Loan ~~was disbursed to us by PNC). At least 60% of such forgiven amount must be used for eligible payroll costs.~~ is 1.0%

On October 5, 2020, we applied for forgiveness on repayment of the ~~loan balance~~PPP Loan as permitted under the ~~program, which is subject to~~Flexibility Act. On July 1, 2021, we were notified by PNC that the review and approval of our lender and the SBA. The approval of the loan forgiveness allows for a maximum period of 150 days from the submittal of a complete loan forgiveness application. If all or a portionentire balance of the PPP Loan ~~is not~~of approximately $5,318,000, along with accrued interest of approximately $63,000 was forgiven ~~all or~~by the ~~remaining portion of~~SBA, effective June 15, 2021. Accordingly, we recorded the ~~loan will be for a term of two years but can be prepaid at any time prior to maturity without any prepayment penalties. The annual interest rate on the~~entire forgiven PPP Loan ~~is 1.0% and no payments~~balance, along with accrued interest, totaling approximately $5,381,000 as “Gain on extinguishment of ~~principal or interest are due until~~debt” on our Consolidated Statement of Operations for the date that the SBA remits the loan forgiveness amount to our lender. While our PPP Loan currently has a two year maturity, the Flexibility Act permits us to request a five year maturity with our lender which we do not expect to request at this time.quarter ended June 30, 2021.

Deferral of Employment Tax Deposits

The ~~CARES Act, as amended by the~~ Flexibility Act provides employers the option to defer the payment of an employer’s share of social security taxes beginning on March 27, 2020 through December 31, 2020, with 50% of the amount of social security taxes deferred to become due on December 31, 2021 with the remaining 50% due on December 31, 2022. We elected to defer such taxes starting in mid-April 2020. ~~We estimate the remaining payment of approximately $1,225,000 of social security taxes otherwise due in 2020 will be deferred with 50% due by December 31,~~At June 30, 2021, ~~and the remaining 50% due by December 31, 2022. At September 30, 2020,~~ we have deferred payment of ~~$838,000~~approximately $1,252,000 in our share of social security taxes, of which ~~amount has been~~approximately $626,000 is included in ~~“other~~“Other long-term ~~liabilities”~~liabilities,” with the remaining balance included in ~~our~~“Accrued expenses” within current liabilities in the Company’s Consolidated Balance ~~Sheet at September 30, 2020.~~Sheets.

Off Balance Sheet Arrangements

From time to time, we are required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. At ~~September~~June 30, ~~2020,~~2021, the total amount of standby letters of credit outstanding totaled approximately ~~$3,026,000~~$3,020,000 and the total amount of bonds outstanding totaled approximately ~~$45,814,000.~~$43,561,000. We also provide closure and post-closure requirements through a financial assurance policy for certain of our Treatment Segment facilities through AIG. At ~~September~~June 30, ~~2020,~~2021, the closure and post-closure requirements for these facilities were approximately ~~$19,651,000.~~$19,898,000.

Critical Accounting Policies and Estimates

There were no significant changes in our accounting policies or critical accounting estimates that are discussed in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020.

Recent Accounting Pronouncements

See “Note 2 – Summary of Significant Accounting Policies” in the “Notes to Consolidated Financial Statements” for the recent accounting pronouncements that have been adopted during the first ~~nine~~six months of ~~2020,~~2021, or will be adopted in future periods.

Known Trends and Uncertainties

Significant Customers. Our Treatment and Services Segments have significant relationships with the U.S and Canadian governmental authorities ~~and continue to enter~~through contracts entered into ~~contracts,~~indirectly as subcontractors for others who are prime contractors or directly as the prime contractor ~~or indirectly for others as a subcontractor~~ to government authorities. As stated previously, our governmental contracts and subcontracts relating to activities at governmental sites in the United States are generally subject to termination or renegotiation on 30 days’ notice at the government’s option, and our governmental contracts/task orders with the Canadian government authorities allow the authorities to terminate the contract/task orders at any time for convenience. Our inability to continue under existing material contracts that we have with the U.S ~~federal~~ government and Canadian government authorities (directly or indirectly as a subcontractor) or significant reductions in the level of governmental funding in any given year could have a material adverse impact on our operations and financial condition. In addition, our U.S. governmental contracts and subcontracts relating to activities at governmental sites are generally subject to termination or renegotiation on 30 days notice at the government’s option. The Task Order Agreements (“TOAs”) with the Canadian government generally provide that the government may terminate a TOA at any time for convenience.

We performed services relating to waste generated by government clients (domestic and foreign (primarily Canadian)), either directly as a prime contractor or indirectly for others as a subcontractor to government entities, representing approximately ~~$28,094,000~~$13,671,000 or ~~93.1%~~84.7% and ~~$70,407,000~~$33,828,000 or ~~91.3%~~86.1% of our total revenues generated during the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, as compared to ~~$19,496,000~~$19,811,000 or ~~86.5%~~89.9% and ~~$41,354,000~~$42,313,000 or ~~80.5%~~90.2% of our total revenues generated during the three and ~~nine~~six months ended ~~September~~June 30, ~~2019, respectively.~~2020.

~~Coronavirus~~COVID-19 Impact. The extent of the impact of the COVID-19 pandemic on our business iscontinues to be uncertain and difficult to predict, as the responses to the pandemic continue to evolve rapidly, especially in light of the recent surge in COVID-19 cases around certain parts of the country. Since the latter part of the second quarter of 2020, all of the projects within our Services Segment that were previously shutdown have restarted as stay-at-home orders and certain other restrictions resulting from the pandemic were lifted. At this time, werapidly. We continue to experience delays in waste ~~shipment~~shipments from certain customers within our Treatment Segment ~~directly~~primarily related to the impact of ~~COVID-19 including generator shutdowns and limited sustained operations, along with other factors. Furthermore, capital markets and economies worldwide~~COVID-19. However, we expect to see returns in waste receipts from these customers in the second half of 2021. Within our Services Segment, we continue to ~~be negatively impacted by~~experience delays in procurement actions and contract awards resulting primarily from the impact of COVID-19 ~~pandemic. Such economic disruption could~~but have ~~a material adverse effect on~~recently begun to receive contract awards. We expect procurement actions and contract awards to continue throughout the second half of 2021. Within our ~~business as our customers could curtail~~Treatment and ~~reduce capital~~Services Segments, we have an unprecedented number of bids currently submitted and ~~overall spending.~~awaiting awards.

The severity of the impact the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, impact from the emergence of new variants of the virus, the extent and severity of the impact on our customers, the impact on governmental programs and budgets, ~~the development/approval~~inoculation rate of ~~treatments or~~the vaccines, and how quickly and to what extent normal economic and operating conditions resume, all of which are uncertain and cannot be predicted with any accuracy or confidence at this time. Our future results of operations and liquidity could be adversely impacted byfrom continued delays in waste shipments, continued delays in procurement actions and contract awards, and/or ~~the~~ recurrence of project work shut downs as well as potential partial/full shutdown of any of our facilities due to COVID-19.

Environmental Contingencies

We are engaged in the waste management services segment of the pollution control industry. As a participant in the on-site treatment, storage and disposal market and the off-site treatment and services market, we are subject to rigorous federal, state and local regulations. These regulations mandate strict compliance and therefore are a cost and concern to us. Because of their integral role in providing quality environmental services, we make every reasonable attempt to maintain complete compliance with these regulations; however, even with a diligent commitment, we, along with many of our competitors, may be required to pay fines for violations or investigate and potentially remediate our waste management facilities.

We routinely use third party disposal companies, who ultimately destroy or secure landfill residual materials generated at our facilities or at a client’s site. In the past, numerous third party disposal sites have improperly managed waste and consequently require remedial action; consequently, any party utilizing these sites may be liable for some or all of the remedial costs. Despite our aggressive compliance and auditing procedures for disposal of wastes, we could further be notified, in the future, that we are a potentially responsible party (“PRP”) at a remedial action site, which could have a material adverse effect.

Our subsidiaries where remediation expenditures will be made are at three sites within our discontinued operations. While no assurances can be made that we will be able to do so, we expect to fund the expenses to remediate these sites from funds generated from operations.

At ~~September~~June 30, ~~2020,~~2021, we had total accrued environmental remediation liabilities of ~~$854,000,~~$781,000, a decrease of $73,000 from the December 31, ~~2019~~2020 balance of ~~$927,000.~~$854,000. The decrease represents primarily payments made on remediation ~~projects for our Perma-Fix of South Georgia, Inc. and Perma-Fix of Dayton, Inc. subsidiaries.~~projects. At ~~September~~June 30, ~~2020, $744,000~~2021, $671,000 of the total accrued environmental liabilities was recorded as current.

Item 3. Quantitative and Qualitative Disclosures about Market Risks

Not required for smaller reporting companies.

Item 4. Controls and Procedures

~~Item 3.~~(a)

~~Quantitative and Qualitative Disclosures about Market Risks~~

~~Not applicable~~

~~Item 4.~~

~~Controls and Procedures~~

~~(a)~~	Evaluation of disclosure controls and procedures.

	We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management. As of the end of the period covered by this report, we carried out an evaluation with the participation of our Principal Executive Officer and Principal Financial Officer. Based on this recent assessment, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) were effective as of ~~September~~June 30, ~~2020~~2021.
(b)	Changes in internal control over financial reporting.

	There was no other change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

~~Item 1.~~

~~Legal Proceedings~~

Item 1. Legal Proceedings

There are no material legal proceedings pending against us and/or our subsidiaries not previously reported by us in Item 3 of our Form 10-K for the year ended December 31, ~~2019 and Part II – Other Information – Item 1 of our Form 10-Q for the quarter ended March 31,~~ 2020. Additionally, there has been no other material change in legal proceedings previously disclosed by us in ~~Part II – Other Information – Item 1 of~~ our Form ~~10-Q~~10-K for the ~~quarter~~year ended ~~June 30, 2020 except the following:~~December 31, 2020.

Item 1A. Risk Factors

During July 2020, Tetra Tech EC, Inc. (“Tetra Tech”) filed a complaint in the United States District Court for the Northern District of California against CH2M Hill, Inc. (“CH2M”) and four subcontractors of CH2M, including the Company (“defendants”). The complaint alleges claims for negligence, negligent misrepresentation and equitable indemnification against all defendants related to alleged damages suffered by Tetra Tech in respect of certain draft reports prepared by defendants at the request of the U.S. Navy as part of an investigation and review of certain whistleblower complaints about Tetra Tech’s environmental restoration at the Hunter’s Point Naval Shipyard in San Francisco.

At this time, we do not believe we have any liability to Tetra Tech. We have provided notice of this lawsuit to our insurance carrier. Our insurance carrier is providing a defense on our behalf in connection with this lawsuit, subject to a $100,000 self-insured retention and the terms and limitations contained in the insurance policy.

~~Item 1A.~~

~~Risk Factors~~

There has been no other material change from the risk factors previously disclosed in our Form 10-K for the year ended December 31, ~~2019 and Form 10-Q for the quarters ended March 31, 2020 and June 30,~~ 2020.

Item 6.

Exhibits

~~(a)~~

~~Exhibits~~

(a)	~~4.1~~	Exhibits

		4.1		Second Amended and Restated Revolving Credit, Term Loan and Security Agreement between Perma-Fix Environmental Services, Inc. and PNC Bank, National Association (as Lender and as Agent), dated May 8, 2020, as incorporated by reference from Exhibit 4.1 to the Company’s Form 10-Q for the quarter ended March 31, 2020 filed on May 12, 2020.
	~~4.2~~	4.2		~~Payment Protection Program~~First Amendment to Second Amended and Restated Revolving Credit, Term ~~Note dated April 11, 2020, by~~Loan and Security Agreement between Perma-Fix Environmental Services, Inc. and PNC Bank, National Association (as Lender and as Agent), dated May 4, 2021, as incorporated by reference from Exhibit ~~99.1~~4.1 to the Company’s Form ~~8-K~~10-Q for the quarter ended March 31, 2021 filed on ~~April 15, 2020.~~May 6, 2021.
	~~10.1~~	4.3		~~Employment Agreement dated July 22, 2020 between Mark Duff, Chief Executive Officer,~~Second Amendment to Second Amended and ~~Perma-Fix Environmental Services, Inc., which is incorporated by reference from Exhibit 99.1 to the Company’s Form 8-K filed on July 27, 2020.~~
	~~10.2~~		~~Employment~~Restated Revolving Credit, Term Loan and Security Agreement dated July 22, 2020 between Louis Centofanti, EVP of Strategic Initiatives, and Perma-Fix Environmental Services, Inc., which is incorporated by reference from Exhibit 99.2 to the Company’s Form 8-K filed on July 27, 2020.
	~~10.3~~		Employment Agreement dated July 22, 2020 between Ben Naccarato, Chief Financial Officer, and Perma-Fix Environmental Services, Inc., which is incorporated by reference from Exhibit 99.3 to the Company’s Form 8-K filed on July 27, 2020.
	~~10.4~~		Employment Agreement dated July 22, 2020 between Andrew Lombardo, EVP of Nuclear and Technical Services, and Perma-Fix Environmental Services, Inc., which is incorporated by reference from Exhibit 99.4 to the Company’s Form 8-K filed on July 27, 2020.
	~~10.5~~		Employment Agreement dated July 22, 2020 between Richard Grondin, EVP of Waste Treatment Operations, and Perma-Fix Environmental Services, Inc., which is incorporated by reference from Exhibit 99.5 to the Company’s Form 8-K filed on July 27, 2020.
	~~10.6~~		2020 Incentive Compensation Plan for Richard Grondin, our new EVP of Treatment Waste Operations, effective January 1, 2020, as incorporated by reference from Exhibit 99.6 to the Company’s Form 8-K filed on July 27, 2020.
	~~10.7~~		~~2020 Incentive Compensation Plan for Chief Executive Officer, effective January 1, 2020, as incorporated by reference from Exhibit 99.1 to the Company’s Form 8-K filed on January 22, 2020.~~
	~~10.8~~		~~2020 Incentive Compensation Plan for Chief Financial Officer, effective January 1, 2020, as incorporated by reference from Exhibit 99.2 to the Company’s Form 8-K filed on January 22, 2020.~~
	~~10.9~~		2020 Incentive Compensation Plan for Executive Vice President of Strategic Initiatives, effective January 1, 2020, as incorporated by reference from Exhibit 99.3 to the Company’s Form 8-K filed on January 22, 2020.
	~~10.10~~		2020 Incentive Compensation Plan for Executive Vice President of Nuclear and Technical Services, effective January 1, 2020, as incorporated by reference from Exhibit 99.4 to the Company’s Form 8-K filed on January 22, 2020.

~~10.11~~		~~Incentive Stock Option Agreement, dated October 19, 2017,~~ between Perma-Fix Environmental Services, Inc. and ~~Richard Grondin,~~PNC Bank, National Association (as Lender and as ~~incorporated by reference from Exhibit 99.11 to the Company’s Form 8-K filed on July 27, 2020.~~Agent), dated August 10, 2021.
~~10.12~~	31.1	Incentive Stock Option Agreement, dated January 17, 2019, between Perma-Fix Environmental Services, Inc. and Richard Grondin, as incorporated by reference from Exhibit 99.12 to the Company’s Form 8-K filed on July 27, 2020.
~~31.1~~		Certification by Mark Duff, Chief Executive Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
~~31.2~~	31.2		Certification by Ben Naccarato, Chief Financial Officer of the Company pursuant to Rule 13a-14(a) or 15d-14(a).
~~32.1~~	32.1		Certification by Mark Duff, Chief Executive Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
~~32.2~~	32.2		Certification by Ben Naccarato, Chief Financial Officer of the Company furnished pursuant to 18 U.S.C. Section 1350.
~~101.INS~~	101.INS		Inline XBRL Instance DocumentDocument-the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document
~~101.SCH~~	101.SCH		Inline XBRL Taxonomy Extension Schema Document*
~~101.CAL~~	101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*
~~101.DEF~~	101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*
~~101.LAB~~	101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document*
~~101.PRE~~	101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*

* Pursuant to Rule 406T of Regulation S-T, the

104

Cover Page Interactive Data File (formatted as an Inline XBRL document and included in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.101).

* Pursuant to Rule 406T of Regulation S-T, the Inline Interactive Data File in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Section 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purpose of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	PERMA-FIX ENVIRONMENTAL SERVICES

Date: ~~November 5, 2020~~August 11, 2021	By:	/s/ Mark Duff
		Mark Duff
		President and Chief (Principal) Executive Officer

Date: ~~November 5, 2020~~August 11, 2021	By:	/s/ Ben Naccarato
		Ben Naccarato
		Chief (Principal) Financial Officer

	Common Stock				Additional Paid-In		Common Stock Held In			Accumulated Other Comprehensive			Non-controlling Interest in			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Treasury			Loss			Subsidiary			Deficit			Equity

Balance at December 31, 2019		12,123,520	$	12	$	108,457	$	(88	)	$	(211	)	$	(1,619	)	$	(77,315	)	$	29,236
Net Income (loss)		—		—		—		—			—			(26	)		1,220			1,194
Foreign currency translation		—		—		—		—			(79	)		—			—			(79	)
Issuance of Common Stock upon exercise of options		3,643		—		6		—			—			—			—			6
Issuance of Common Stock for services		5,128		—		48		—			—			—			—			48
Stock-Based Compensation		—		—		44		—			—			—			—			44
Balance at March 31, 2020		12,132,291	$	12	$	108,555	$	(88	)	$	(290	)	$	(1,645	)	$	(76,095	)	$	30,449
Net Income (loss)		—		—		—		—			—			(29	)		204			175
Foreign currency translation		—		—		—		—			28			—			—			28
Issuance of Common Stock upon exercise of options		241		—		—		—			—			—			—			—
Issuance of Common Stock for services		10,239		—		56		—			—			—			—			56
Stock-Based Compensation		—		—		48		—			—			—			—			48
Balance at June 30, 2020		12,142,771	$	12	$	108,659	$	(88	)	$	(262	)	$	(1,674	)	$	(75,891	)	$	30,756
Net Income (loss)		—		—		—		—			—			(32	)		1,446			1,414
Foreign currency translation		—		—		—		—			11			—			—			11
Issuance of Common Stock for services		9,592		—		62		—			—			—			—			62
Stock-Based Compensation		—		—		69		—			—			—			—			69
Balance at September 30, 2020		12,152,363	$	12	$	108,790	$	(88	)	$	(251	)	$	(1,706	)	$	(74,445	)	$	32,312

Balance at December 31, 2018		11,944,215	$	12	$	107,548	$	(88	)	$	(214	)	$	(1,495	)	$	(79,630	)	$	26,133
Net loss		—		—		—		—			—			(30	)		(672	)		(702	)
Foreign currency translation		—		—		—		—			12			—			—			12
Issuance of Common Stock for services		24,964		—		60		—			—			—			—			60
Stock-Based Compensation		—		—		48		—			—			—			—			48
Balance at March 31, 2019		11,969,179	$	12	$	107,656	$	(88	)	$	(202	)	$	(1,525	)	$	(80,302	)	$	25,551
Net income (loss)		—		—		—		—			—			(31	)		289			258
Foreign currency translation		—		—		—		—			(4	)		—			—			(4	)
Issuance of Common Stock for services		17,902		—		62		—			—			—			—			62
Stock-Based Compensation		—		—		36		—			—			—			—			36
Issuance of Common Stock with debt		75,000		—		263		—			—			—			—			263
Issuance of warrant with debt		—		—		93		—			—			—			—			93
Balance at June 30, 2019		12,062,081	$	12	$	108,110	$	(88	)	$	(206	)	$	(1,556	)	$	(80,013	)	$	26,259
Net income (loss)		—		—		—		—			—			(29	)		1,768			1,739
Foreign currency translation		—		—		—		—			4			—			—			4
Issuance of Common Stock for services		15,337		—		60		—			—			—			—			60
Stock-Based Compensation		—		—		45		—			—			—			—			45
Balance at September 30, 2019		12,077,418	$	12	$	108,215	$	(88	)	$	(202	)	$	(1,585	)	$	(78,245	)	$	28,107

	Employee Stock Option Granted
	Nine Months Ended September 30,
	2019
Weighted-average fair value per share	$	1.46
Risk -free interest rate ⁽¹⁾		1.4%-2.58	%
Expected volatility of stock ⁽²⁾		48.67%-51.38	%
Dividend yield		None
Expected option life ⁽³⁾		5.0 years

	Outside Director Stock Option Granted
	Nine Months Ended September 30,
	2020			2019
Weighted-average fair value per share	$	4.66		$	2.27
Risk -free interest rate ⁽¹⁾		0.59%-1.61	%		2.08	%
Expected volatility of stock ⁽²⁾		55.83%-56.68	%		54.28	%
Dividend yield		None			None
Expected option life ⁽³⁾		10.0 years			10.0 years

	Three Months Ended September 30,							Nine Months Ended September 30,
(In thousands)	2020		2019		Change			2020		2019		Change
Administrative	$	20	$	6	$	14		$	64	$	20	$	44
Treatment		49		85		(36	)		194		367		(173	)
Services		7		—		7			119		—		119
PF Medical		81		74		7			221		228		(7	)
Total	$	157	$	165	$	(8	)	$	598	$	615	$	(17	)